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Abstract
Despite advances in therapy, acquired immune deficiency syndrome 
(AIDS) continues to be a global problem. New therapeutic avenues are being 
explored, including dendritic cell (DC)-based immunotherapy. While DCs can 
efficiently promote an immune response, their limited lifespan within the lymph
node represents an obstacle to efficient immunotherapy.
;
We examined different gene transfer methods, observing lentiviral 
transduction to be the most effective. Transduction using generated lentiviral 
transfer vectors encoding M11L and EGFP were used to determine effects on 
cellular viability. We did not observe significant differences in viability following 
apoptosis induction in transduced L cells. In primary DC cultures, transduction 
with and without M11L did not influence DC maturation or longevity in either the 
short or long term, though transduction was more efficient in the immature DC 
population. These results demonstrate that transduction is effective for gene 
transfer into DCs. However, techniques for dual gene expression mustbe further 
refined.
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Overview
Since the discovery of acquired immune deficiency syndrome (AIDS) in 
the 1980s, it has evolved from a disease associated primarily with the 
homosexual population to a global pandemic. According to the 2010 World 
Health Organization AIDS epidemic report, approximately 33.3 million people 
worldwide are living with Human Immunodeficiency Virus (HIV); In 2009, 1.8 
million deaths were attributed to AIDS while 2.6 million new cases were 
described (1). ^  J . ,,
The increase in people living with HIV can be in part attributed to 
improvements in therapy; as of 2008, 42% of infected individuals had access to 
therapy. This therapy does not however clear any HIV reservoirs, and 
interruptions in therapy are followed by rapid increases in viremia. Furthermore, 
various social, economical, and medical reasons result in problems in patient 
compliance to therapy. As such, development of an alternative means of HIV 
therapy is required in order to limit our reliance on antiretroviral therapy. 
Unfortunately, development of HIV vaccines using traditional approaches has 




HIV, the causative agent of AIDS, was first isolated in 1981 (2). Initially, it 
was characterized by two independent groups as a retroviral infection caused by 
a virus similar to human T cell leukemia virus (HTLV)-1, and causing
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lymphadenopathy and physical weakness. The virus was termed HTLV-III by the 
group of Robert Gallo (3), and lymphadenopathy-associated virus (LAV) by the 
group of Luc Montagnier (4). Further studies eventually revealed that the two 
viruses were indeed the same, and in 1986, they were named HIV. The virus was 
classified into the genus Lenf/V/'rus, part of the Retroviridae family.
The virus possesses a number of both structural and non-structural genes 
that allow it to subvert an anti-HIV immune response and to persist in the body. 
These genes are all encoded on the genomic positive-sense RNA, which exists 
as a homodimer within a mature virion. The three main regions of the HIV 
genome are termed gag, pol, and env (5). The gag region encodes proteins that 
are responsible for providing the physical infrastructure of the virus. This 
infrastructure includes capsid and nucleocapsid proteins that comprise a conical 
shell that encases the genomic RNA homodimer (6). The pol gene encodes the 
viral enzymes reverse transcriptase, integrase, and the protease that cleaves 
newly synthesized polyproteins. The env region encodes gp160, the precursor to 
the envelope proteins gp120 and gp41. Also within the HIV genome are coding 
regions for different non-structural proteins. Regulatory proteins such as tat and 
rev are responsible for a number of steps in the viral life cycle, ranging from 
increasing the level of transcription of HIV RNA to manipulation of viral nucleic 
acid export (7, 8). Lastly, other accessory proteins such as vpr, vif, nef, and vpu 
can function to subvert normal host immune function and cause the release of 
newly synthesized viral particles (9).
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Infection by HIV begins by transmission of the virus through several 
identified routes. The most common of which is through sexual contact where 
secretions from an infected individual come into contact with mucosal 
membranes of uninfected persons (10). However, transmission through blood 
and blood products is also common, such as through practices of needle sharing 
among intravenous drug users or bad hygienic practice including the reuse of 
needles (11). Infected mothers can also transfer the virus vertically to the fetus or 
during pregnancy (12, 13). Following transmission, the virus attaches to the : 
target cell via an interaction between gp120 and host cell CD4, using CCR5 and 
CXCR4 chemokine receptors as a coreceptor (14). Further studies have shown, 
however, that gp120 is also capable of using other cell surface molecules as a 
receptor, including heparan sulfate, galactosyl ceramide, DEC205, and DC- 
SIGN. The latter two molecules are expressed on dendritic cells (DCs) (15-18).
Following binding of the virus, it then enters the cells. The predominant
belief is that this occurs by fusion of the cellular lipid membrane and the lipid
\
envelope of the virus, releasing the nucleocapsid into the target cell (19). 
However, more recent studies have described an alternate mechanism where 
bound virus is endocytosed by the cell in a clathrin dependent manner (20).: 
Following entry, the capsid is disassembled and reverse transcriptase mediates 
reverse transcription of the genomic RNA into single stranded cDNA, then into 
double stranded linear form, and lastly into a double stranded linear form, which 
is imported into the nucleus and is integrated into the target cell by the viral 
integrase. After integration, the proviral DNA is transcribed to genomic and
subgenomic mRNA, spliced, and translated by the standard cellular machinery, 
leading to production of Tat and Rev. The production of Tat leads to the 
upregulation of proviral transcription, while Rev allows for the export of unspliced 
mRNA. The unspliced mRNA is used to generate Gag, which encases the full- 
length RNA genome, and Env polyprotein. The HIV protease processes the Env 
polyprotein to gp41 and gp120 subunits which are transported to the plasma 
membrane. Gag and Gag-Pol polyproteins associate with the HIV genomic RNA 
at the plasma membrane in areas enriched for the HIV Env protein as the virus 
begins to bud off from infected cells, ultimately released by Vpu. Maturation of 
the virion is completed as the viral protease processes the polyproteins into their 
functional forms.
Following infection, the individual enters the acute stage of infection. This 
is characterized by a phase of robust virus replication, accompanied with a 
marked drop in CD4+ T cells (21). In the acute phase, CD8+ T cells are weakly 
mobilized, which provide small amounts of control of infection (22). After several 
weeks, infected individuals enter the latent phase of infection. This is 
characterized by a steady increase in viral load and a decrease in CD4+ T cell 
count. When CD4+ T cell levels drop to below 200 cells/pL from the normal range 
of 800-1050 cells/pL he infected individual is said to progress to AIDS (23, 24). 
Here, CD4+ mediated immunity is no longer effective, resulting in a large 
increase in susceptibility to normally innocuous infections.
Methods to counteract infection or disease progression fall into two 
categories, prophylactic or therapeutic. Whereas the ultimate goal in prophylaxis
4
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is the prevention of infection, therapeutics serve to control an existing infection. 
To date, in the context of HIV infection, the options available in either case are 
limited. Currently, a number of problems inherent to HIV have prevented the 
formulation of an effective prophylactic treatment. The greatest hurdle to a 
prophylactic vaccine has been the incredible diversity of HIV (25). A number of 
factors contribute to the high degree of heterogeneity of HIV. Firstly, the reverse 
transcriptase enzyme that generates the cDNA for integration lacks proofreading 
ability, resulting in an error rate of 30 mutations per 1x106 base pairs (26, 27). 
This is further enhanced by a high rate of viral turnover and by a high virus 
burden within an individual (28, 29). Secondly, HIV is prone to antigenic shift; 
coinfection with viruses belonging to different phylogenetic lines can recombine 
during the strand transfer involved in reverse transcription, leading to alterations 
in fitness and virulence (30, 31). As a result of the high variability, envelope 
glycoproteins that would be most accessible to neutralizing antibodies display an 
astonishing 20% variability in amino acid sequence within a given clade (32). 
When comparing isolates across clades, this number increases to greater than 
35% (32). Consequently, prophylactic treatments would have to be capable of 
inducing an immune response against all of the different HIV subtypes across the 
many phylogenetic branches. Because of the difficulties in doing so, more focus 
has been placed on the treatment of existing infection.
Control of HIV Replication
, Generally, the immune response to virus infection utilizes both a humoral 
and cell mediated response. The humoral response generates antibodies which
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can bind to free virus particles and prevent further infection (33). The cellular 
response utilizes cytotoxic cells, CD8+T cells or natural killer cells, to destroy 
infected cells expressing viral antigens (34, 35). While the goal of a prophylactic 
vaccine would serve to increase the major histocompatibility complex (MHC)- 
ll/CD4+ humoral axis of the response, therapeutic vaccines should increase the 
MHC-1/CD8+ cellular axis.
Activation of a cytotoxic T lymphocyte (CTL) response is dependent on an 
interaction between the CD8+ T.cells and a peptide-MHC-l. Upon infection, viral 
peptides synthesized by infected cells can be loaded onto MHC-I during transit to 
the plasma membrane. The peptide-MHC complex can then be presented to 
CD8+ T cells leading to their activation and effector function. DCs, the most 
potent antigen presenting cell (APC) are capable of eliciting strong cellular 
responses. However, their interactions with CD4+ T cells represent a double- 
edged sword, in that they can also facilitate transmission of the virus (36).
The CD8+ T cell response appears to be very important in the control of 
lentiviral replication and disease progression. During acute infection, the CTL 
response follows the increase in plasma viral load (37, 38). The peak of the CTL 
response is concordant with a drop in virus load. A study using a primate simian 
immunodeficiency virus (SIV) infection model showed that depletion of CTLs 
during the acute phase of infection leads to failure of early HIV control (39). 
Transient depletion of CD8+ T cells during the chronic phase of infection resulted 
in increased viremia, which was eventually suppressed with reappearance of 
CD8+ T cells (40). Further evidence of the importance of CD8+ T cells is
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observed in long term nonprogressors (LTNPs). These individuals are infected 
with HIV, but maintain a very low viral titer and prolonged time before 
progression to AIDS. CTL levels in this group are similar to those in other HIV 
infected individuals; however, the difference lies in the effector capacity of the 
CTLs. In LTNPs, levels of perforin, a pore forming protein directed by effector 
CTLs towards target cells, are increased (41). .
As a consequence of CD4+ T cell depletion, insult to the humoral immune 
response is observed as well. However, in contrast to a cellular response, a 
neutralizing antibody response was not observed to play a role in HIV 
suppression in elite controllers and those on long-term highly active antiretroviral 
therapy (HAART)-treated patients (42). Furthermore, the generated antibody 
response has been observed to be unable to match the rate of virus escape and 
to be lacking in breadth (43, 44). This may be a result of effects of HIV on the B 
cell response, as the diminished responses are associated with abnormal B cell 
phenotypes (45). Recently, new neutralizing antibody clones have been 
observed following screening of 1800 infected donors, as well as a class of 
individuals termed ‘elite neutralizers’ (46, 47). These findings demonstrate that 
an effective neutralizing response is possible and that it may be harnessed for 
future therapy.
HIV Therapy
Major advances to date in the field of HIV therapy have been the 
development of pharmacological treatments. The first antiretroviral drugs
targeted the reverse transcriptase enzyme. These were nucleoside reverse 
transcriptase inhibitors (NRTIs) that competed with standard nucleotides during 
elongation of DNA strands (48). These nucleoside analogs lacked a 3’-OH group, 
preventing elongation of the cDNA strand generated during reverse transcription. 
Later generations of reverse transcriptase inhibitors were composed of 
nucleotide analogs and non-nucleoside inhibitors (nNRTIs). While nucleotide 
analog inhibitors function in the same manner as nucleoside inhibitors, the non­
nucleoside inhibitors function by binding directly to the enzyme to inhibit catalytic 
activity (49). Protease inhibitors were the next class of antiretrovirals made.
These drugs target the viral protease to prevent the processing of nascent 
polyproteins(50). This targeting prevents the functional proteins from being 
incorporated into assembled virions. Entry inhibitors, specifically fusion inhibitors, 
are one of the newest classes of antiretrovirals, with the first one being passed 
by the US Foodand Drug Administration (FDA) in 2003 (51). These drugs 
function by targeting components of the infection synapse between virus and 
target cell. The newest class of antiretroviral drug is the integrase inhibitor, first 
licensed by the FDA in 2007 (52). These drugs prevent the integration of the 
reverse transcribed cDNA into the host genome.
These drugs, in particular NRTIs, nNRTIs, and protease inhibitors are 
used in HAART, the current standard of HIV therapy. Treatment with single drugs 
is not used, as the high mutation rate and heterogeneity of HIV within an infected 
individual ultimately gives rise to a drug resistant mutant. However, by using 
combination therapy, the probability of obtaining a progeny virion with mutations
8
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conveying resistance to all drugs in the cocktail is considerably lower. 
Administration of an effective HAART regimen results in an increase in CD4+ T 
cells and restoration of pathogen-specific immune responses. Ultimately, full 
recovery cannot be achieved, due in part to incomplete control of HIV replication 
as well as the ability of the virus to remain in various cellular reservoirs in the 
body (36).
It has been demonstrated that although HAART dramatically decreases 
the HIV plasma viral load, interruption of therapy results in a rapid return of high- 
level viremia (53). Reservoirs of latent virus are believed to be generated in CD4+ 
T cells, monocytes/macrophages, DCs, and some subsets of CD34+ 
hematopoietic stem cells early in the disease course (54-57). It is believed that 
the main compartment for latency is the population of resting memory CD4+ T 
cells. Because these cells perform only the basic processes required to survive, it 
is likely that the virus will simply persist in the proviral form, without high levels of 
virus production.
Strict adherence to HAART is required to prevent viral rebound and 
emergence of drug resistant mutants due to reservoirs of latent virus. The 
International AIDS Society has recommended at least 95% adherence for optimal 
results in antiretroviral therapy, as modest or occasional nonadherence 
significantly decreases the benefits of HAART (58). However, compliance with an 
optimal regimen is difficult. Studies have shown common reasons for 
nonadherence were sleeping through dose times, difficulties in following special 
instructions, and changes in one’s daily habits. Social issues surrounding
nonadherence include the treatment being a reminder of one’s HIV positivity, 
others knowing of one’s HIV status, and a lack of complete understanding of their 
own treatment (59-61). These issues are in addition to complications caused by 
the side effects associated with HAART and the financial burden of treatment. 
Although effective, the difficulties of a HAART regimen underline the need for a 
simpler therapeutic approach.
Vaccine Strategies
One of the major goals in the field of HIV therapy is the development of an 
effective vaccine. Previous attempts at doing so have made use of traditional 
approaches of vaccine design: live attenuated virus, whole killed virus, and 
protein subunit vaccines. Live attenuated virus vaccines make use of virus 
particles that have diminished pathogenicity and/or a reduced ability to replicate. 
Whole killed viruses, while also composed of intact viral particles, are non- 
infectious. Thus, killed viruses would be unable to infect host cells. Protein 
subunit vaccines are composed entirely of one or more subunits of an intact virus 
particle. The subunits used are often those that are normally easily accessible to 
neutralizing antibodies. There are also a number of novel vaccine strategies that 
are being assessed. These include plasmid DNA vaccines, viral vector based 
vaccines, and dendritic cell based immunotherapy. Regardless of the vaccine 
strategy used, effective CD8+T cell activation is required.
Preliminary research employing live attenuated virus vaccines in an 
SIV/macaque model showed that these vaccines do confer a small level of
10
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protection (62). An advantage of this type of vaccine is that the attenuated virus 
is capable of infecting host cells and generating viral proteins that can be 
presented within the context of MHC-I, leading to the activation of a CD8+ T cell 
response. However, long term observation demonstrated that vaccinated 
macaques still exhibited immune dysfunction, T cell depletion, and in some 
cases, progression to AIDS. Ultimately, the immunocompromised state of the 
host combined with the high level of replication and selective pressure can result 
in reversion to virulent progeny (63, 64). Consequently, this vaccine modality is 
not suitable for prophylactic or therapeutic purposes.
Inactivated virus vaccines have proven to be useful in preventing infection 
in the case of polio and influenza, but have not been effective thus far with HIV 
(65-67). These vaccines are produced by heat or chemical inactivation of 
infectious virus. One of the major difficulties in the use of this vaccine method in 
the context of HIV is the conservation of immunogenicity, particularly when
discussing the structure of the envelope proteins (68). Nevertheless, attempts to
\
study the feasibility of killed virus vaccines have been assessed in SIV models. 
Separate studies have shown that depending on the method of inactivation, 
these vaccines can result in a modest increase in neutralizing antibody titer, and 
decrease viremia if administered post-challenge (69, 70). In humans, this method 
was unable to generate a broad antibody response (66). Furthermore, there was 
an inability to promote a CD8+ T cell mediated response due to a lack of 
antigenic epitope presentation through the MHC-I pathway.
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Subunit vaccines are also often used for viruses such as hepatitis B (71). 
These vaccines consist of formulations of highly purified viral proteins, commonly 
the structural glycoproteins present within the HIV envelope. Initial trials of 
subunit vaccines composed of recombinant HIV gp120 have shown an increase 
in neutralizing antibody titer towards a homologous vaccine strain, but not 
against heterologous virus (72, 73). Further studies using a trimeric HIV gp140 
(gp120 elongated with the gp41 ectodomain) vaccine in rabbits and macaques 
have shown only low levels of neutralizing antibody towards heterologous virus 
(74). The difficulty in all of these methods is an overall inability to account for the 
high level of variability in the HIV envelope glycoproteins (75, 76). To address 
this problem the use of cocktails of HIV envelope glycoproteins from prevalent 
HIV strains has been explored (77). While this method did elicit neutralizing 
antibody responses, further studies have to be undertaken to better understand
' S'
the breadth of these responses.
DNA vaccines are composed of plasmid vectors engineered to encode
\
immunogenic proteins. The immunogenic properties of DNA vaccines were first 
observed when mice vaccinated with plasmids encoding the human growth 
hormone gene, rather than showing increased human growth hormone 
production, were observed to produce antibodes targeting the hormone itself 
(78). However, further studies later showed that in order to obtain detectable 
immune responses in primates, large amounts of plasmid DNA were required. As 
such, research in this field is also focusing on the development of adjuvants and 
novel delivery methods to increase efficiency and potency.
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Viral vectors have also been examined for HIV therapy for their ability to 
act as a vehicle of gene delivery (79-81). Vaccines utilizing viral vectors consist 
of viruses modified to be safe, exhibit zero to low toxicity, and encode the 
requisite genes, as a vehicle to deliver the genetic information. As these viruses 
are able to infect target cells and express the foreign proteins, the belief was that 
they would be able to elicit a T cell response. One of the more publicized 
attempts was the Merck STEP trial (82). This trial attempted to utilize 
recombinant adenovirus vectors to deliver the gag, pol, and nef genes and 
induce anti-HIV T cell immunity. Infection of human immune cells with the viral 
vectors was intended to result in expression of the viral antigens and a 
subsequent immune response. However, during phase III clinical trials, no 
protection or significant reductions in the plasma viral load post-infection was 
observed; rather, the vaccinated group was seen to have an increased number of 
new infections relative to the control group (83).
Dendritic Cell Immunobiology
DCs are the immune system’s most potent and versatile APC. They are 
able to quickly sense inflammatory stimuli, capture antigen, transport it to 
secondary lymphoid organs, and mobilize antigen specific T cells (84-86). 
Because of their important role in immune surveillance, they localize to peripheral 
tissues including the skin, respiratory tract, and genito-urinary mucosa where 
they exist predominantly as immature cells. Here, they express low levels of 
surface molecules involved in the co-stimulation and activation of naïve T cells 
such as CD80 and CD86. However, they have a high capacity for sampling their
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extracellular environment for antigens. Upon exposure to pro-inflammatory 
molecules such as those involved in tissue damage or pathogen associated 
molecular patterns (PAMPs), the DCs are activated and undergo a change in 
function and phenotype (87, 88). In this state, endocytic activity decreases, while 
co-stimulatory molecules increase. Furthermore, the migratory capacity of the 
DCs increases, permitting them to traffic to secondary lymphoid organs. This is 
mediated by an increase in cell surface chemokine receptors, notably CCR7 (89). 
Within the secondary lymphoid organs, the activated DCs are capable of driving 
Th1 differentiation through production of interleukin (IL)-12 (90-93). This permits 
the activated DCs to initiate an immune response along both cellular and 
humoral axes. Due to the level of influence that DCs have on the immune 
response, they have attracted attention as a therapeutic target for the treatment 
of disease.
In addition to the aforementioned interactions of DCs with CD8+ T cells, 
DCs are also capable with interacting with CD4+ helper T cells through an
\
interaction with MHC-II. This leads to either cellular immunity mediated by Th1 
cells, or a B cell response via the Th2 subset. The cytokine environment 
influences the nature of the T helper response, as Th1 responses are promoted 
by interferon (IFN)-y and IL-12, whereas an IL-4 promotes a Th2 response (93, 
94). Activation of Th1 cells by DCs leads to increased macrophage activity and 
proliferation of CD8+ T cells (95). Conversely, activated Th2 generate a humoral 
response by interacting with antigen bound MHC-II on the surface of B cells
present in secondary lymphoid organs. The Th2 cells then deliver activating 
signals to the B cells resulting in their activation and proliferation (96).
Ultimately, T cell activation by DCs is dependent on their activation state. 
Previous research has demonstrated that DCs lacking the means to respond 
directly to PAMPs retain the ability to be partially activated (termed “matured”) via 
other hematopoietic cells (97). In this scenario, other hematopoietic cells 
encounter pathogens and following interactions between PAMPs and the 
appropriate receptors, release pro-inflammatory cytokines that promote DC 
maturation. The matured DCs differ from activated DCs in the capacity to 
generate effector T cells. Both mature and activated DCs are capable of 
providing a costimulatory signal to resting T cells due to upregulation of CD80 
and CD86, which interact with CD28 on T cells. Notably, matured DCs fail to 
produce IL-12, and are hence unable to drive T cell differentiation (90, 91). 
Furthermore, the mature DCs have been shown to be unable to prime effective 
CD8+ T cells, resulting in a defective CTL response (98-101).
Dendritic Cell-based Therapeutics
The use of DCs in gene therapy often involves the introduction of a gene 
or protein product encoding a given immunogen (102). Initial attempts at antigen 
loading have used purified peptides, viral vectors for transduction, or antigen 
expressing cell extracts. Following loading, the antigen can be presented on 
surface MHC molecules. Proteins synthesized within the cell are loaded onto 
MHC-I, whereas exogeneous proteins are loaded onto MHC-II. Furthermore,
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DCs are also capable of cross-presentation, where they are able to capture 
extracellular antigens, process them, and load them onto MHC-I for presentation 
to CD8+ T cells. Antigen presenting DCs can traffic to regional lymph nodes, and 
present the loaded antigen to T cells to initiate a response (103-105). Depending 
on the context of antigen presentation, DCs can activate either a Th2 response 
leading to a humoral CD4+ T cell response, or a Th1 response leading to a CD8+ 
T cellular response.
As it is the manner in which antigen is presented by DCs that decides on 
either a cellular or humoral immune response, different strategies of DC 
preparation can be employed to generate either response. As cellular immune 
responses generally depend on the production of endogeneous antigen and its 
subsequent loading onto MHC-I, and humoral responses use exogeneous 
derived antigen loaded onto MHC-II, different antigen loading strategies can be 
used to achieve the desired response. In the former, genes encoding the antigen 
of interest can be transferred into DCs such that they will be able to produce the 
resulting protein on their own (106). Following generation of the protein, it can be 
processed and loaded within the cell onto surface bound MHC-I, and stimulate 
CTLs. Loading of MHC-II can be achieved by pulsing DCs with antigenic 
peptides. It has been shown that DCs pulsed ex vivo with cell wall constitutents 
from Streptococcus pneumoniae and administered into syngenic mice resulted in 
strong B cell response to capsular polysaccharides and microbial proteins of the 
bacterium (107). Additionally, different subsets of DCs can be used to prepare
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the vaccine. It has been observed that Langerhans cells preferentially prime 
cellular immunity, whereas dermal DCs prime humoral immunity (108).
Engineering of DCs for use in vaccine preparations must fulfill a number of 
requirements. A sufficient number of DCs must be prepared for purposes of both 
manipulation and ensuring that enough DCs will be obtained to traffic to regional 
lymph nodes. They must express immunogenic peptides within the appropriate 
MHC context in order to initiate the correct type of immune response. Lastly, they 
must be activated in order to prime effector cells (109).
One of the major advances in the DC immunotherapy field was the 
discovery that DCs could be easily generated from precursor CD14+ monocytes 
by culturing in the presence of IL-4 and granulocyte macrophage colony- 
stimulating factor (GM-CSF) (110, 111). Further refinement of this technique has 
allowed for the large-scale generation of commercial grade monocyte-derived 
DCs. It is also possible to generate myeloid DCs using CD34+ hematopoietic 
stem cells and expand them in a similar manner, using IL-4, GM-CSF, and TNF 
in the culture medium (112,113). However, the advantages of either CD14+ 
derived DCs or CD34+ derived DCs over the other in the context of HIV has yet 
to be studied. In addition to using either CD14+ or CD34+precursors, different 
subsets of DCs can be generated by modifying the cytokine milieu in culture 
(114). These different subsets carry with them different immunostimulatory 
properties; however, the exact subset that would be best for HIV therapy is not 
clear.
The DC precursors must also be HIV-free If used to generate large 
populations. As CD14+ and CD34+ are susceptible to HIV infection, use of 
infected precursor cells can generate HIV infected DCs that would propagate the 
virus and exacerbate disease an HIV-positive individual. Furthermore, research 
has shown that interaction between infected DCs and infected CD4+ T cells 
results in the stimulation of HIV replication and virion synthesis (115, 116). 
Because of the hazards of using infected DCs, it is important to be able to v 
generate healthy, uninfected cells. In order to do so, uninfected precursors must 
be utilized. These can be cells taken from an infected individual and rigorously 
screened, or from an MHC-compatible, uninfected donor.
The DCs must be activated in order to achieve optimal T cell activation. 
Otherwise, immature DCs are unable to initiate the appropriate immune response 
and may be tolerogenic (117). Thus, in order to obtain potent, stimulatory DCs, 
they are often treated with combinations of toll-like receptor (TLR) ligands and 
inflammatory cytokines. A number of studies have made use of poly l:C (TLR 3 
agonist), CpG (TLR 9 agonist), tumor necrosis factor (TNF)a, interferon (IFN)y, 
IL-6, IL-1(3, and prostaglandin E2 (PGE2)(118). The combination of cytokines 
and TLR ligands can mimic interactions between DCs and pathogens, to promote 
increases in costimulatory molecules and chemokine receptors.
Different combinations of TLR ligands and cytokines have been assessed 
for clinical use. It has been recently reported that the use of purified TLR ligands 
is not without drawbacks. Purified poly l:C, a TLR3 ligand, when used in a 
maturation cocktail has been shown to induce an antiviral state within the DC
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(119, 120). Activation of these innate immune mechanisms may cause RNA 
degradation or inhibition of protein synthesis, limiting expression of introduced 
transgenes. To circumvent this, the use of clinical grade sources o f TLR ligands 
has been studied, namely cocktails present in existing vaccine formulations such 
as the typhoid fever vaccine, a seasonal influenza vaccine, and the bacillus 
Calmette-Guerin vaccine. (118). The findings here show that the “vaccine 
matured" DCs are capable of inducing Th1 polarization, but with limited CCR7 
expression. The limitation in migratory capacity was restored by supplementing 
with PGE2, enhancing CCR7 expression to increase responsiveness to lymph 
node-associated chemokines (121).
A number of studies have examined the potential to use DCs as HIV 
vaccines. Initial trials made use of allogeneic DCs from HIV negative individuals 
and autologous DCs. The DCs were loaded with either envelope gp160 or 
synthetic peptides corresponding to HIV-gag or pol. These DCs were injected 
into 6 human leukocyte antigen (HLA) identical HIV infected individuals (122). 
One of the recipients of allogeneic DCs demonstrated increased envelope- 
specific CTL and lymphocyte-proliferative responses accompanied with IFN-y 
and IL-2 production. Another recipient of allogeneic DCs showed increased 
envelope-specific lymphocyte-proliferative response. A recipient of autologous 
DCs eventually showed an increase in peptide-specific lymphocyte-proliferative 
responses. However, in all cases, no effect on viral load was observed. Another 
trial used monocyte-derived DCs cultured in the presence of GM-CSF and IL-4 
(123). Eighteen HIV infected individuals off HAART treatment for at least 6
months were given DCs loaded with inactivated HIV and cytokine matured. At 
112 days post administration, a decrease in plasma HIV RNA was measured with 
8 of the 18 recipients demonstrating a reduction of viral load of over 90%. This 
correlated with increased HIV-specific CD4+ T cells. These results demonstrated 
the efficacy of a DC-based HIV vaccine to control HIV infection.
Manipulation of Dendritic Cell Lifespan
One of the key issues surrounding the use of DCs in immunotherapy is 
their lifespan and persistence within the lymph node (124). Furthermore, uptake 
of dead DCs by immature DCs may result in tolerance (125). Because the lymph 
node is the site of antigen presentation, it has been postulated that a limited 
lifespan of DCs places limits on the duration of a T-cell mediated immune 
response. Characterization of BrdU-labeled DCs in the absence of antigen or 
microbial stimuli demonstrated that they can persist anywhere between 2 and 9 
days within lymphoid organs. Following antigenic and microbial stimuli however, 
the turnover rate increased (126). Other studies using fluorescently-labeled 
allogeneic murine DCs revealed that injected DCs are short lived upon migration 
to the lymph node persisting for upwards of 7 days, with peak levels achieved at 
day 2 (127). Multiple attempts have been made at circumventing shortcomings in 
DC lifespan. These include transfection with a number of cellular anti-apoptotic 
factors such as Bcl-2 and Bcl-xL, or siRNA-mediated knockdown of the pro- 




Manipulation of cellular apoptotic regulators to boost DC longevity is in 
itself a double-edged sword. Although they have been shown to successfully 
increase longevity, they may also be associated with oncogenicity, making 
applications involving these difficult to translate to clinical settings (132, 133). 
Furthermore, depending on the method of transgene introduction, effects of 
manipulated apoptotic factors may synergize with other proto-oncogenes whose 
expression may be altered following gene transfer. An alternative method makes 
use of apoptotic regulators that are viral in nature. The benefits of this method 
exist on two levels. First, it allows for the selection of regulators that are not 
known to have oncogenic potential. Second, as the regulators are viral and 
therefore foreign to the body, it is possible for the immune system to eventually 
eliminate cells expressing the foreign protein. This permits a temporary increase 
in DC longevity without resulting in overwhelming DC activity or an excessively 
prolonged lifespan that could contribute to cancer.
Myxoma virus encodes M11L, an anti-apoptotic protein encoded by a virus
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not known to be pathogenic to humans. It has shown to be important to myxoma 
virus pathogenicity as an M11L deletion mutant virus was markedly less 
pathogenic than wild type virus, being unable to cause lethal myxomatosis (134). 
Furthermore, the knockout virus resulted in unusual lesions with vigorous 
inflammatory activity, suggesting that M11L performed a function that normally 
compromises an effective cellular response. Research later showed that M11L 
was localized to the mitochondria (135). Mitochondria are central in the apoptotic 
pathway, where it functions in both the intrinsic and extrinsic pathways (136).
During apoptosis, the mitochondria swell, as well as changes in membrane 
potential. Pores formed in the mitochondrial membrane result in the release of 
cytochrome c and subsequent activation of caspase 9. The pores are formed by 
apoptotic factors Bak and Bax, while local anti-apoptotic factors, the Bcl-2 family 
of proteins, prevents their activation (137, 138). M11L was revealed to be a 
structural homolog of Bcl-2, functioning by preventing the conformational 
activation of Bak and Bax (139, 140) and the subsequent release of cytochrome 
c (141). Pharmacological induction of apoptosis in immortalized Rat2 fibroblasts 
infected with an M11L encoding retrovirus resulted in a 2-fold decrease in 
apoptotic cells over a 5 hour treatment, demonstrating its1 anti-apoptotic effects 
(135). ■ ,
In the context of DC-based HIV therapy, anti-apoptotic regulators such as 
M11L may play a pivotal role. It has been demonstrated that the HIV envelope 
glycoprotein gp160 is capable of inducing apoptosis in CD4+ T cells (142). 
Presumably, DCs engineered to express the same envelope glycoprotein would 
meet the same fate. However, the ability of M11L to prevent apoptosis may 
circumvent this problem. Previously, it was shown that inclusion of M11L in a 
DNA vector-based HIV vaccine was able to prevent gp140 mediated cytotoxicity, 
as well as increase the magnitude of a CD8+ T cell response (143). This study 
made use of a plasmid DNA vaccine encoding both gp140 and M11L. As the 
ultimate fate of the vector following administration was unknown, it was 
postulated that the vector was endocytosed by DCs. These cells would then
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synthesize and express the HIV glycoprotein while utilizing the anti-apoptotic 
effects of M11L to circumvent gp160 mediated cytotoxicity.
Dendritic Cell Gene Transfer
DC immunotherapy requires that the DCs are engineered to present 
immunogenic peptides on surface MHC. A number of different methods exist for 
gene transfer, generally classified as either non-viral or viral vector mediated. 
Commonly used non-viral mediated transfer methods include liposome or 
cationic-polymer mediated, and more recently, Nucleofection. Viral vectors used 
for transduction of cells primarily make use of either adenovirus or lentivirus.
Liposome-mediated transfection entails the use of DNA enclosed within 
positively charged vesicles made of a phospholipid bilayer. Upon interaction with 
the cell membrane, the two lipid bilayers fuse, releasing the DNA contents into 
the cytoplasm (144). The DNA is then imported into the nucleus, where it persists 
as an episome. This method is one of the most common, as it displays a high 
transfection efficiency in a wide variety of cell lines, and is of low toxicity to the 
cell. However, it does not display high transfection efficiencies in primary cells. 
Several groups have attempted to use this method to transfect monocyte-derived 
DCs, observing transfection efficiencies only as high as 10% (145).
Cationic polymers make use of charge differences between positively 
charged molecular polymers and negatively charged nucleic acid (146). The 
polymer and nucleic acid complex are endocytosed by the cell. Proton sponge 
effects of the cationic polymer buffer the endosomal pH and result in massive
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proton accumulation and chloride Influx (147). The change In osmotic pressure 
across the endosomal membrane eventually causes rupture of the membrane, 
releasing the nucleic acid. Plasmid DNA is then imported into the nucleus where 
It, as in lipofection, persists as an episome. Studies using this method in AG101 
cells, an immortalized murine DC line, demonstrated a transfection efficiency 
below 1 % (148).
Nucleofection is a relatively new transfection method. Rather than 
electroporation, where application of an electric current pulses nucleic acids into 
the cytoplasm, Nucleofection pulses nucleic acids directly into the nucleus (149). 
In the case of DNA, it can then be transcribed faster, resulting in quicker gene 
expression. Furthermore, Nucleofection demonstrates higher transfection 
efficiency across many cell types (150). A major disadvantage of the system is its 
proprietary nature and inability to customize parameters of the electric current.
Viral vector-mediated transduction makes use of viruses engineered to 
encode a gene of interest that infect the cells. In general, plasmids encoding the 
transgene and viral components are transfected into a mammalian cell line that 
packages and releases vial particles. The viral particles can then be harvested 
and used to transduce the cells of interest. However, as the transduction vehicles 
are still viral in nature, a number of safety measures are put In place to prevent 
pathogenicity. Often, the viruses used as vectors are either known to not cause 
severe pathology, or are prepared such that they are unable to do so (151).
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Lentivirus transduction is a popular method of gene transfer. Importantly, 
because lentiviruses are capable of integration, they are well suited for infecting 
dividing cells and propagating engineered transgenes (152). This system utilizes 
three separate plasmids, a transfer plasmid encoding the integration cassette, a 
packaging plasmid encoding the gag, pol, tat, and rev proteins to provide the 
capsid structure, transcription and integration machinery (153), and trans- 
activating proteins to drive expression of the integration cassette, and an 
envelope plasmid that encodes the vesicular stomatitis (VSV)-G protein to 
pseudotype the recombinant virus. The pseudotyping of the virus permits an 
expanded tropism, allowing the lentiviral vector to be used for transducing a wide 
range of cell types (152). As the natural life cycle of lentiviruses involves the 
integration of the viral genome into the host genome, there are safety concerns 
surrounding this method. In a trial using lentiviral vectors to treat X-linked 
adrenoleukodystrophy, transduced CD34+ hematopoietic stem cells yielded 
leukocytes of high polyclonality and no clustering of insertions in oncogenes or 
growth-related genes (154). Conversely, in a trial using lentiviral vectors to treat 
P-thalassemia, transduced CD34+ stem cells demonstrated clonal dominance by 
transductants containing an activating insertion in the HMGA2 proto-oncogene 
(155). Although the abundance of the dominant transduced clone was stable for 
months after its discovery, this highlights the potential for insertional activation. It 
is therefore important to recognize the safety concerns of lentiviral transduction. 
The main concerns have been the generation of replication-competent virus and 
insertional activation of oncogenes, in part by viral enhancer and promoter
sequences. However, further advancement of this technology has resulted in the 
development of new safety measures to address some of the concerns (152,
156, 157).
Although HIV is In fact a member of the lentivirus family, a number of 
safety measures have been putln place In the generation of lentiviral - 
transduction vectors. In each progressive generation of lentiviral vector, :
researchers have been able to dispense with a number of HIV-1 genes...........
Currently, only the genes absolutely required for the initial generation of the viral 
particle and subsequent Infection are present (158). Most importantly, the newer 
generation lentivirus vectors are self-inactivating (157). The transfer plasmid 
coding for the gene of interest possesses a deletion in the 3’ long terminal repeat 
(LTR). After assembly of the virus particles and subsequent infection Into target 
cells, the deletion is copied Into the 5’ region during the reverse transcription 
phase of Infection prior to Integration. As a result, the integrated provirus lacks a 
complete 5’ LTR capable of driving transcription and therefore is unable to 
support production of lentiviral transcripts capable of being packaged Into 
progeny virions. Therefore no new Infectious virus can be produced.
Dual Gene Expression
For gene therapy, It may be necessary to express multiple transgenes if 
more than one gene Is required to establish the Intended effect. Introduction of 
multiple genes can be achieved either by the use of multiple vectors, or by a 
single multicistronic vector. However, if multiple monocistronic vectors are used,
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only a fraction of the target cells will acquire all of them, resulting in a , 
heterogeneous population of unequal gene expression. For this reason, a single 
multicistronic vector is appealing as target cells taking up the vector will result in 
a largely homogeneous population of transgene-expressing cells.
Some viruses have evolved ways to initiate translation in the absence of a 
5’ cap, permitting translation from within an mRNA transcript. This is achieved by 
the presence of an internal ribosome entry site (IRES) (159). Further research 
has demonstrated the existence of this system within eukaryotic cells; however, 
the mechanism of viral IRES function is better understood (160). In general, the 
IRES functions by creating a scaffold within an mRNA transcript to permit protein 
translation independent of a 5’cap or a number of cellular translation initiation 
factors; the exact mechanism, however, is dependent on the origin of the IRES. 
The level of expression of the second gene under control of the IRES can be 
variable; in the case of the encephalomyocarditis virus IRES, expression can 
range anywhere between 6 and 100% that of cap-dependent translation from the 
cytomegalovirus (CMV) promoter, depending on cell type and the gene in 
question (161).
Another method of dual gene synthesis is to have each gene underthe 
control of its own promoter. However, the use of different promoters can result in 
protein expression levels that are also dependent on cell-type. Furthermore, 
promoter interference can occur, where the transcription from one promoter can 
interfere with that of the other (162, 163). Recently, Amendola et al. described 
the use of a synthetic bidirectional promoter for use in a lentiviral transfer vector
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(164). The synthetic promoter consisted of an ‘efficient’ promoter, either the 
human ubiquitin C or phosphoglycerate kinase (PGK) promoters, joined in 
opposite orientation to a minimal core promoter derived from CMV. The upstream 
elements contained in the ‘efficient’ promoter, effectively flanked by two core 
promoters, could then drive transcription in both directions.
Project Rationale
A previous study from our laboratory described the pHERO DNA plasmid 
vaccine system (143). The plasmid backbone encodes genes promoting 
episomal stability allowing it to replicate in dividing cells. In this study, the 
pHERO plasmid, encoded M11L as well as gp140, a secretable form of HIV 
gp120 also containing the gp41 ectodomain. Inclusion of M11L in this vector 
resulted in decreased levels of HIV envelope glycoprotein-mediated apoptosis, 
as well as an increase HIV-specific CD8+ T cell response (143). In conjunction 
with boosting with a canarypox virus encoding the HIV envelope glycoprotein, 
gag, and a portion of the protease gene, the effects were further increased. The 
presence of M11L also stimulated expansion of the central and effector memory 
CD8+ T cell populations. In this study, the DNA vector was administered 
intramuscularly following cardiotoxin treatment. Cardiotoxin treatment caused 
local inflammation, promoting infiltration of inflammation responsive cells. It was 
postulated that the infiltrating cells, namely DCs, were responsible for uptake of 
the DNA vector, and subsequent synthesis of immunogenic peptides and 
presentation to Th1 cells in the context of MHC-I. Furthermore, as gp140 is a 
secretable form of HIV Env, it is possible that muscle cells that took up the
vaccine subsequently produced and secreted gp140. Regional APCs would then 
be able to take up the secreted protein and cross-present it to T cells in the 
lymph node while increases in longevity mediated by M11L may Increase 
persistence within the lymph node. This would then lead to increased antigen 
presentation, and the stronger immune response.
In order to recapitulate this effect specifically in DCs, It is necessary to find 
an efficient method to transfer the appropriate genes into them. Furthermore, 
because coordinate expression of multiple genes is desired, the vector of choice 
must be multicistronic. In the case of a lentivirus vector, the two genes can be 
under the control of two promoters functioning bidirectionally, or a single 
promoter and an IRES between the genes. Different methods of both gene 
transfer and vector organization have to be assessed in order to determine the 
most effective way of obtaining suitable HIV gene expression and 
transfection/transduction efficiency.
Hypothesis and Objectives
Based on what has been shown about M11L and the previous findings 
concerning its use in the pHERO system, I hypothesize that expression of M11L 
in DCs results in increased DC longevity. To test my hypothesis, I have set a 
number of research objectives for this project. First, I will identify an effective 
method of gene transfer into DCs. By assessing a number of different gene 
transfer methods, I should arrive at one that provides sufficient gene transfer 
efficiency while also preserving cell viability. Secondly, I have to optimize
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conditions coordinate dual-gene expression. Lastly, I will assess the effects of 
lentiviral transduction on DCs in culture from both a short-term and long-term 
perspective. Refinement of this system can demonstrate a novel method of 
boosting antigen presentation, especially in cases such as HIV where 
immunizing peptides may be cytotoxic. This can serve as a foundation for future 
studies of DC-based therapies.
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Materials and Methods 
Cell Culture
HEK293T (human embryonic kidney cells) and L cells (rat fibroblasts) 
were maintained in-reconstituted powdered Dulbecco’s Modified Eagle’s Medium 
(DMEM; Invitrogen) prepared according to manufacturer’s instructions and 
supplemented with 10% FBS, 10mg/mL penicillin-streptomycin, and 200mM L- 
glutamine (complete DMEM).
DC2.4 (immature C57BL/6 mouse DCs) cells (165)were maintained in 
Roswell Park Memorial Institute (RPMI) 1640 culture medium supplemented with 
10% fetal calf serum, non-essential amino acids, L-glutamine, sodium pyruvate, 
penicillin-streptomycin, and (3-mercaptoethanol (complete RPMI 1640).
Transfection
Non-viral transfection methods were carried out in DC2.4 cells, an 
immortalized immature murine DC cell line (165). Transfection with v 
Lipofectamine (Invjtrogen) was carried out according to manufacturer’s 
instructions. Briefly, 2 x 106 cells were placed into each well of a 6-well plate in 
1.5mL of complete RPMI1640. Plasmid (4 pg) and 10pL of Lipofectamine were 
each mixed into 250pL of serum free RPMI 1640. After 5 minutes of incubation, 
the diluted DNA and Lipofectamine were combined, and incubated for 20 
minutes. The liposome-DNA complexes were then added dropwise to each well. 
After 24 hours, media was removed and replaced with fresh complete RPMI 
1640. Analysis was performed 48 hours after transfection.
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Transfection with Turbofect (Fermentas) was performed according to the 
manufacturer’s instructions with some minor modifications. Twenty-four hours 
prior.to transfection approximately 2 x 106 DC2.4 cells were plated in 4mL of 
complete RPMI 1640. At the time of transfection, 4pg of plasmid DNA was diluted 
in 400uL serum free RPMI 1640. Six microliters of Turbofect was then added to 
the diluted DNA sample, vortexed, and incubated at room temperature for 20 
minutes. The DNA-polymer complexes were then added dropwise to the wells. 
Analysis was performed 48 hours after transfection.
Nucleofection
Nucleofection was performed according to manufacturer’s instructions 
using the mouse DC Nucleofector kit (Lonza). Approximately 2.5 x 105 cells were 
resuspended in 100pL nucleofection solution. 2pg of DNA was then added to the 
cell suspension, and transferred to an Amaxa certified cuvette. The cells were 
transfected with the program Y-001for immature DCs. Pre-warmed (400pL) 
complete RPMI 1640 was added after Nucleofection to each cuvette. The x 
transfected cell suspension was added to 400uL of pre-warmed complete RPMI 
1640 in a 48 well plate. Analysis was performed 24 hours after Nucleofection.
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Generation of Lentiviral Transfer Vectors
IRES containing vectors were based on the pCCL-rHER2/neu-IRES-M111- 
transfer vector provided by the laboratory of Dr. Jeffrey Medin at the University of 
Toronto. To generate the pCCL-EGFP vector, the rHER2/neu gene and the 
IRES-M11L fragment were excised using Asc I and Sal l-HF (New England
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Biolabs), and purified the vector backbone by agarose gel electrophoresis 
followed by gel extraction using a QIAquick Gel Extraction Kit (QIAGEN). The 
enhanced green fluorescence protein (EGFP) gene was amplified from the 
pEGFP-N1 expression vector (Clonetech) using primers containing a 5’ Asc I site 
and a 3'Sal I site (GAGGGCGCGCCATGGTGAGCAAGG and ; 
AGGGTCGACTTACTTGTACAGC). The PCR product was then ligated into the 
linearized pCCL vector backbone. The assembled plasmid was electroporated 
into Stbl-4 electrocompetent E. coli cells (Invitrogen), and correctness verified by 
restriction digest, PCR, and DNA sequencing.
To generate the pCCL-EGFP-IRES-M11L fragment, the IRES-M11L 
cassette was amplified by PCR from the original pCCL-rHER2/neu-IRES-M111- 
vector using primers containing a 5’ and 3’ Sal I site 
(TTCTTGTCGACGCCCCTCTCCCTCCCCCCCCC and 
TTCTTGTCGACGCGGCCGCCTAGGTCCCTCGGT). The pCCL-EGFP vector 
was linearized using Sal I and treated with calf intestinal alkaline phosphatase 
(Invitrogen) to prevent self-ligation. The treated linear plasmid was purified by 
phenol-chloroform extraction. The amplified IRES-M11L fragment was digested 
with Sal I and ligated into the dephosphorylated linear pCCL-EGFP vector 
imediately downstream of the EGFP coding region. The assembled plasmid
was electroporated into Stbl-4 E. coli electrocompetent cells and verified by 
restriction digest, orientation specific PCR, and DNA sequencing.
Generation of the pCCL-EGFP-minCMV-hPGK-M11L vector began with 
the pCCL-EGFP-minCMV-hPGK-Luc bidirectional transfer vector supplied by the
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laboratory .of Dr. Jeffrey Medin. The M11L fragment was amplified from a purified 
IRES-M11L fragment using PCR with primers containing a 5’Pst I site and a 3’Sal 
I (AG G C CTG C AG AT G ATGTCTC GTTT A M G  AC G G and GGTAGTCGACC 
TAGGTCCCTCGGTACCATTTT) site. The luciferase gene was excised from the 
starting plasmid using Pst I (Invitrogen) and Sal l-HF (New England Biolabs), and 
the vector backbone was purified by agarose gel electrophoresis followed by 
extraction using the PureLink Quick Gel Extraction Kit (Invitrogen). The M11L 
fragment was ligated into the linearized backbone and transformed into 
chemically competent DH5a E. coli cells (Invitrogen). The plasmids were verified 
by restriction digest and DNA sequencing.
Protein Extraction and Immunoblotting
Transfected or transduced cells were washed twice with ice-cold 
phosphate buffered saline (PBS) and lysed on the plate with RIPA buffer 
supplemented with 1 tablet of 50x complete protease inhibitor. After incubation 
on ice for 20 minutes, cell lysates were centrifuged at 16000 x g for 10 minutes at 
4°C. Supernatants were transferred to new tubes, and protein concentration was 
quantified by Bio-Rad protein assay using an Ascent Multiskan (Thermo 
Scientific). Samples were stored at-80°C.
Soluble proteins (20pg) were subjected to SDS-PAGE using a 16% 
denaturing gel and transferred to a polyvinylidene difluoride FluoroTrans W 
membrane (Pall Scientific). Immunoblotting was performed using a 1:100 dilution 
of rabbit anti-M11L polyclonal antibody (134), and a 1:5000 dilution anti-GAPDH
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antibody (Sigma), followed by 1:10000 dilutions of a goat-anti-rabbit or goat-anti­
mouse secondary antibody conjugated to 800nm and 680nm infrared dyes 
respectively (LiCor Biosciences, donated by the laboratory of Dr. Stephen Barr, 
University of Western Ontario). Proteins were visualized using a LiCor Odyssey 
Infrared Imaging System.
Production of Lentiviral Vectors
The construct pMDG was used to generate the VSV-G viral envelope 
protein, while the gag, pol, and rev genes were expressed from pCMV. The 
transfer vectors used were the generated pCCL-EGFP, pCCL-EGFP-IRES- 
M11L, pCCL-EGFP-hPGK-minCMV-Luc and pCCL-EGFP-hPGK-minCMV-M11L.
In brief, 15cm2 tissue culture treated dishes were seeded with 
approximately 15 x 106 low passage HEK293T cells 6 hours prior to transfection 
in complete DMEM. The envelope plasmid (pMDG; 3.8pg), packaging plasmid 
(19.01pg), and transfer plasmid (19.01pg) were suspended using 150mM NaCI 
to a volume of 1.125mL, and added 126nmol of polyethylenimine (Sigma Aldrich) 
dissolved in a total of 1.125mL. The transfection mixture was vortexed, added to 
the cells, and incubated overnight at 5% C02 and 37°C. The next morning, media 
was discarded and replaced with 15mL of fresh complete DMEM. At 25 hour 
intervals following the initial media change, culture supernatants were collected 
and replenished up to 3 times. Collected supernatants were filtered through a 
0.45pm filter, and stored at 4°C prior to concentration.
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To concentrate virus, 30mL of supernatant was subjected to , 
ultracentrifugation for 2.5 hours at 4°C and 25 OOOrpm in an SW-28 rotor using a 
Beckman LM-8 ultracentrifuge. Pellets were resuspended in 100pL of Hank’s 
buffered saline solution (HBSS) supplemented with 5% bovine serum albumin 
(BSA; HBSS/BSA). Pellets were pooled, re-aliquoted in lOOpL volumes, and 
stored at -80°C. To avoid repetitive freeze-thaw cycles, all thawed vials were 
subsequently stored at 4°C for further use.
To titer concentrated and unconcentrated virus, approximately 8 x 105 
HEK293T cells were seeded onto 6-well plates at least 4 hours prior to 
transduction. At the time of transduction, media was removed and replaced with 
1mL of media containing serial 10-fold dilutions of virus and 8pg/mL of protamine 
sulfate. Following overnight incubation, media was removed and replaced with 
4mL of complete DMEM. After an additional 24 hours, virus was titered by 
counting of EGFP-positive foci by fluorescent microscopy.
Cell Transduction
Transduction of primary bone marrow derived DCs (BMDCs) was 
performed immediately following DC enrichment. Two million BMDCs were 
added to each well of a 6 well plate. Lentivirus was added at a multiplicity of 
infection (MOI) of 5, supplemented 10pg/mLwith DEAE-dextran, in a culture 
volume of 1mL of complete RPMI plus 4ng/mL IL-4 and 1000U/mL GM-CSF. At 
16 hours after infection, 3mL of complete RPMI plus IL-4 and GM-CSF was 
added to cells.
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Transduction of L cells was performed by adding 2 x 106 cells to each well 
of a 6 well plate. Cells were given at least 6 hours to adhere to the plate. Media 
was then removed and virus was added at an MOI of 5 supplemented with 
8pg/mL of protamine sulfate:(Sigma Aldrich) and complete DMEM to a total 
culture,volume of 1mL; At 16 hours post infection, media was removed and 
replaced with 2mL of fresh DMEM.
Induction of Apoptosis
L cells were transduced with pCCL-EGFP orpCCL-EGFP-IRES-M11L at 
an MOI of 5. After 48 hours, cultures were treated with staurosporine (STS; 
Invitrogen) dissolved in dimethyl sulfoxide (Bioshop; DMSO) at a final 
concentration of 4pM for 8 hours. Following the treatment time, supernatants and 
floating cells were retained, and attached cells were washed with PBS and lifted 
using 0.25% trypsin-EDTA. All cells were washed 2 times with PBS, once with 1X 
binding buffer (BD Pharmingen) and resuspended to make 100pL aliquots in flow 
cytometry tubes. Levels of apoptosis were assessed via staining for 7- 
aminoactinomcin D (7-AAD; 1:20, BD Pharmingen) and annexin V-PE (1:20; BD 
Pharmingen). Excess stain was washed once and resuspended in 400pL of 1X 
binding buffer. Stained cells were run through a BD FACS Calibur and analyzed 
using FlowJo software (TreeStar).
Mouse Bone Marrow DC Isolation and Culture
Mice were used in accordance with protocols approved by the University 
of Western Ontario Animal Care and Use Subcommittee. Bone marrow was
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isolated from femurs and tibias of 6 to 8-week old C57B1/6 mice as previously 
described (166). Briefly, bone marrow cells were cultured for 4 days in complete 
RPMI supplemented with the 1000 U/mL of GM-CSF and 4ng/mL of IL-4 
(donated by Schering-Plough via Dr. Peta J. O’Connell). At day 4, dendritic cells 
were enriched by centrifugation over a 13.5% histodenz gradient (25 min, 500 x
g)-
Cell Staining and Flow Cytometry
Cells were prepared for flow cytometry by washing approximately 2 x 106 
cells in a 6-well plate with ice cold HBSS supplemented with 1% BSA. Lightly 
attached cells were removed by gentle pipetting. Cells were then washed 3 times 
with HBSS+BSA and 5 minute 500 x g centrifugations. Cell pellets were 
resuspended in 1 mL HBSS/BSA and blocked with 50pL normal goat serum. Cells 
were then washed, and resuspended to make 100pL aliquots into flow cytometry 
tubes. Cells were then stained with CD86-PerCP (1:400; BioLegend), CD11c-PE 
(1:600; BioLegend), and Far Red Live/Dead Viability dye (1:4500; Invitrogen). 
Excess antibody was washed, and pelletted cells were resuspended in 300pL 
HBSS, and fixed with an additional 100pL of 4% paraformaldehyde dissolved in 
PBS. Stained cells were run through a BD FACS Calibur and analyzed with 
FlowJo Software (TreeStar).
Statistics
GraphPad Prism 4 software was used to perform one way analysis of 
variance (ANOVA) testing with Tukey's post test when comparing 3 or more
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groups, two way ANOVA testing with Bonferroni post test in two variable 
experiments, and student’s T test when comparing 2 groups. Data are presented 
as group means with ± standard error. Unless otherwise stated, data are 
representative of n=3 where n represents the number of independent
significant.
Results ■>-
Non-viral Transfection Methods Are Not Effective in DCs
To asses the efficiency of gene transfer into DCs, a number of non-viral 
vector-mediated transfection methods were attempted. To perform these studies,
I used DC2.4 cells, an immortalized line of immature murine dendritic cells (165).
I tested three of the more common transfection methods: cationic polymer 
transfection, liposome mediated transfection, and nucleofection. In order to 
obtain both gp140 and M11L expression, I used the previously characterized 
pHERO-M11L-gp140-CpG-EGFP (143) in conjunction with a control EGFP 
expression vector, pEGFP-N1. In the case of nucleofection, the control vector 
used was the manufacturer’s supplied pMAX-GFP expression vector. EGFP 
expression was determined by flow cytometry, and viability was assessed by 
staining with 7-AAD.
Cationic polymer-mediated transfection was performed on DC2.4 cells
\
using Turbofect, a new transfection reagent marketed by Fermentas (Fig. 1). The 
reagent control resulted in a viability of 86.1±4.3%. Viability following transfection 
with the control pEGFP-N1 was seen to be 61.8±16.8%. When the pHERO- 
M11 L-gp140-CpG-EGFP vector was used, viability dropped further to 
55.2±19.4%. Statistical analysis proved these differences to not be significant. 
However, there did appear to be a slight trend towards a lower viability upon 
transfection of the expression plasmids. To determine transfection efficiency, I 
gated on viable 7-AAD' cells and the sizes of the EGFP+ populations were
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Figure 1 -  Cationic polymer mediated transfection does not result in significant 
levels of pHERO transfection in DC2.4 cells. DC2.4 cells were transfected with 
pEGFP-N1 or pHERO-M11 L-gp140-CpG-EGFP using the cationic polymer 
solution, Turbofect. Forty-eight hours following transfection, cells were collected 
and analyzed for viability and GFP expression by flow cytometry. (A) 
Representative flow cytometric density plots showing viable (7-AAD' cells) and 
pooled data from 3 independent experiments showing the mean ± standard error. 
(B) Representative flow cytometric plots showing GFP expressing cells as a 
percentage of viable cells as gated in A, and pooled data from 3 independent 
experiments. One way ANOVA testing was performed to determine any 









assessed. More transfectants were observed when using the pEGFP-N1 control 
vector, with approximately 9.4±7.0% of viable cells being transfected. However, 
use of the pHERO-M11L-gp140-CpG-EGFP vector resulted in a lower, though 
statistically insignificant, level of transfection, as only 2.2±1.0% of viable cells 
expressed EGFP as determined by one way ANOVA.
Liposome mediated transfection was performed in DC2.4 cells using the 
commercially available reagent Lipofectamine 2000 from Invitrogen (Fig 2). This 
reagent is among the most common used for transfection, normally capable of 
transfecting a wide variety of cell lines. As in the case of the Turbofect reagent, 
treatment with Lipofectamine alone did not result in a large loss in viability 
(93.5±1.7%). When the pEGFP-N1 vector was used in transfection, viability 
decreased significantly to 77.3±5.5%. The drop in viability was more evident 
when transfecting the pHERO-M11L-gp140-CpG-EGFP vector, as viability 
decreased to 73.4±4.1%. I then examined the percentage of viable cells that also 
expressed EGFP. As I observed with the Turbofect reagent, the pEGFP-N1 
vector was transfected at a slightly higher efficiency than pHERO-M11L-gp140- 
CpG-EGFP, 7.5±3.8% compared to 2.4±1.4%. However, this difference was not 
observed to be statistically significant as determined by one way ANOVA.
I also attempted to use Nucleofection developed by Amaxa due to its 
reputation of being able to transfect “hard-to-transfect” cells (Fig.3). However, it is 
important to note that Nucleofection utilizes the smallest number of starting cells 
(2.5 x 105). As a transfection control, I utilized the pMAX-GFP expression vector 
supplied by Amaxa. Nucleofection of DC2.4 cells in the absence of plasmid was
Figure 2 -  Liposome mediated transfection does not result in significant levels of 
pHERO transfection in DC2.4 cells. DC2.4 cells were transfected with pEGFP-N1 
or pFIERO-M11L-gp140-CpG-EGFP using the liposome solution, Lipofectamine 
2000. Forty-eight hours following transfection, cells were collected and analyzed 
for viability and GFP expression by flow cytometry. (A) Representative flow 
cytometric density plots showing viable (7-AAD' cells) and pooled data from 3 
independent experiments showing the mean ± standard error. (B) Representative 
flow cytometric plots showing GFP expressing cells as a percentage of viable 
cells as gated in A, and pooled data from 3 independent experiments. One way 
ANOVA testing was performed to determine any significant differences between 





Figure 3 -  Nucleofection is not effective in DC2.4 cells. DC2.4 cells were 
transfected with pMAX-GFP or pHERO-M11L-gp140-CpG-EGFP via 
Nucleofection. Twenty-four hours following transfection, cells were collected and 
analyzed for viability and GFP expression by flow cytometry. (A) Representative 
flow cytometric density plots showing viable (7-AAD' cells) and pooled data from 
3 independent experiments showing the mean ± standard error. (B) 
Representative flow cytometric plots showing GFP expressing cells as a 
percentage of viable cells as gated in A, and pooled data from 3 independent 
experiments. One way ANOVA testing was performed to determine any 






shown to result in 69.2±2.3% viability, suggesting that the pulsing is more 
cytotoxic than both Lipofectamine and Turbofect alone. Inclusion of any of the 
plasmids significantly reduced viability, as nucleofection of pMAX-GFP resulted 
in 46±6.1% viability, and 35.8±2.1% when using pHERO-M11 L-gp140-CpG- 
EGFP. Nucleofection of the GFP control plasmid occurred at an efficiency of 
72.5±14.9%. However, there was a large decrease in transfection efficiency 
when using the pHERO-M11L-gp140-CpG-EGFP, as only 0.6±0.1% of viable 
cells expressed EGFP.
Generation of Lentivirus Transfer Vector
In addition to non-viral methods of gene transfer, I also attempted to use 
lentiviral vectors to transduce the DCs. This method necessitated the 
construction of transfer vectors encoding the integration cassette to be included 
into the virus particle.
IRES-containing vectors were constructed starting from the pCCL- 
rHer2/neu-IRES-M11L vector obtained from Dr. Jeffrey Medin’s laboratory 
(University of Toronto). The integration cassette of this vector contained 
rHer2/neu downstream of the elongation factor 1 alpha (EF1a) promoter, flanked 
by a 5’ Asc I site and a 3’ Sal I site, and an IRES-M11L fragment immediately 
downstream of rHer2/neu, flanked at both 5’ and 3’ ends with an Asc I site. I 
excised both fragments by Asc l/Sal I double digest, and amplified the EGFP 
gene from the pEGFP-N1 vector, including a 5’ Asc I site and 3’ Sal I site. The 
EGFP fragment was ligated to the pCCL backbone. PCR amplification of the
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Figure 4 -  Generation of pCCL-EGFP lentiviral transfer vector. The pCCL 
backbone was obtained by digesting a pCCL-rHer2/neu-IRES-M11L lentiviral 
transfer vector. EGFP was ligated downstream of the EF1a promoter. (A) 
Agarose gel electrophoresis of PCR amplification products using EGFP-specific 
primers. Red square denotes clone used in sequencing. L represents DNA size 
ladder. C represents control pEGFP-N1 vector. (B) Sequence comparison of 





> E F l a l p h a  GTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTA TGGCCCTTGCGTGCCTT 300> p C C L -£ G F P  GTNCCGWWNGTNGT-CCCGCGMKC-TGGCNTCNTTHMGGNTTJîi— GGCCCTW CGTW CCT- 70
** *** ** ** ****** * **** ** ** ** * * ** * *** ***
> E F l a l p h a  GAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTG 360> p C C L -E G F P  GAATTACTNCCNCCNNGCTGCAGTACGTGATTNTNNATCCCGAGCTTCGGGTTGGAAGTG 130
* * * * * * * *  **  **  * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * *
> E F l a l p h a  GGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGG 420> p C C L -E G F P  GGTGGGAGAGTTCGAGGCCTTGCGCTTÀÀGGAGCCCCTTCGCCTCGTGCTTGAGTN GÀGG 190
***** ***** ***** ****** ***** ***** ***** ***** ****** ***** ***  ****
> E F l a l p h a  CCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCG 480> p C C L -E G F P  CCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCN CCTTCGCGCCTGTCTCG 2 S0
****************************************** *****************
> E F l a l p h a  CTGCTTTCGATA AGTCTCTAGCCATTTA AAATTTTTGATGA CCTGCTGCGACGCTTTTTT 540> p C C L -E G F P  CTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGN CCTGCTGCGACGCTTTTTT 310
***** ***** ***** *** ** **** ***** ***** ***** *  *******************
> E F l a l p h a  TCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTG 600> p C C L -E G F P  TCTGGCAAGATAGTCTTGTÀAATGCGGGCCAAGATCTGCACÂCTGGTATTTCGGTTTTTG 370
***** ***** ***** *** ***** *** ***** ***** ***** ***** ***** ***** ****
> E F l a l p h a  GGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACA TGTTCGGCGAGGCGGGGCC 660> p C C L -E G F P  GGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCÀCA TGTTCGGCGAGGCGGGGCC 430
***** ***** ***** *** ***** *** ***** ***** ***** ***** ***** ***** ****
> E F l a l p h a  TGCGAGCGCGGCCACCGA GAA TCGGA CGGGGGTAGTCTCAA GCTGGCCGGCCTGCTCTGG 720> p C C L -E G F P  TGCGAGCGCGGCCÀCCGA GAÂ TCGGA CGGGGGTAGTCTCAÀ GCTGGCCGGCCTGCTCTGG 490
************************************************************
> E F l a l p h a  T G CCT GGCCTCGCGCCGCCGTGTA TCGCCCCGCCCTGGGCGGCA A GGCTGGCCCGGTCGG 780> p C C L -E G F P  T G CCT GGCCTCGCGCCGCCGTGTA TCGCCCCGCCCTGGGCGGCA A GGCTGGCCCGGTCGG 550
***** ***** ***** *** ***** ***** *** ***** ***** ***** ***** ***** ****
EGFP insert revealed an 850bp fragment in lanes 7, 11, 12, and 13, consistent 
with the size of gene (Fig. 4A). Further verification of the promoter was done by 
sequence alignment of the sample in lane 7 with the consensus sequence of the 
EF1a promoter (Fig 4B). Although gaps in the sequence were observed, the 
presence of the correct nucleotides was verified using alternate primers.
To generate pCCL-EGFP-IRES-M11L, the obtained pCCL-EGFP vector 
was linearized using Sal I and treated with calf alkaline phosphatase to prevent 
self-ligation. The IRES-M11L fragment was generated by PCR amplification 
containing Sal I sites at both 5’ and 3’ ends. After ligation, presence of the insert 
was determined by PCR amplification using primers at the 3’ end of EGFP and 
the 3’ end of M11L (Fig. 5A). As expected, I observed a band at a size of 
approximately 2kb in lane 10. DNA sequencing was performed and that of the 
generated vector was aligned with the sequence of the IRES-M11L fragment 
(Fig. 5B). Errors were observed in the IRES sequence, possibly influencing levels 
of M11L expression.. However, misread nucleotides and sequencing gaps may 
also be a product of the complex secondary structure inherent to the IRES 
region. The cloned M11L was, however, seen to match the consensus sequence 
(Accession number: M93049).
In addition to the IRES containing vectors, I generated a bicistronic 
transfer vector (pCCL-EGFP-minCMV-hPGK-M11L) utilizing a bidirectional 
promoter. We amplified the M11L gene from a previously purified IRES-M11L 
fragment adding a 5’ Pst I site and 3’ Sal I site. Starting from a pCCL-EGFP- 
minCMV-hPGK-Luc vector, the luciferase gene was excised using Pst I and Sal I.
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Figure 5 -  Generation of pCCL-EGFP-IRES-M11L lentiviral transfer vector. The 
IRES-M11L fragment was amplified by PCR and ligated into pCCL-EGFP 
immediately downstream of EGFP. (A) Agarose gel electrophoresis PCR 
amplified IRES-M11L using orientation specific primers. L corresponds to DNA 
size ladder. Red box denotes clone selected for sequencing. (B) Sequence 
comparison of IRES-M11L sequence with the selected pCCL-EGFP-IRES-M11L
clone.
pCCL-EGFP-IRES-MllL
> IR E S - H lIL> p C C L -E G F P -1 R E S-H IIL ------------------------------------------------------------------------------- GTCGACGCCCCTCTCCCT 18f^îNNNNWWNWHI'ÎNHfÎtJHWJWNNTG™'IGAî'.ICTGTACAWGTÀAGTCGACGCCCCTCTCCCT 60
* * * * * * * * * * * * * * * * * *
M R E S - H llL> p C C L -£ G F P -1RE S-M lIL CCCCCCCCCCTÀACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCT 78 CCCCCCC--CTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCT 118 * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
>IRES-H 11L> p C C L -E G F P -IR E S -H l1 L ATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCC 138 ATATGTTGTTTTCCACCATATTGCCGTCTTTTGGCÀATGTGAGGGCCCGGAAACCTGGCC 178 * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
>IRES-H 11L> p C C L -E G F P -IR E S -H l1 L CTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTC 198 CTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTC 238 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
M R E S - H llL> p C C L -E G F P -IR E S -H l1 L TGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTG 258 TGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTG 298 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
M R E S - H llL> p C C L -E G F P -IR E S -H l1 L TAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACÀGGTGCCTCTGCGGCCAÀA 318 TAGCGACCCTTTGCAGGCAGCGGAACCCCTCACCTGGCGACAGGTGCCTCTGCGGCCAAA 358 * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
>IRES-M 11L> p C C L -E G F P -IR E S -H l1 L AGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTT 378 AGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTT 418 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
> IR E S -H l1 L
>pCCL-EGFP-IR E S -H l1 L GGATAGTTGTGGAAAGàGTCAà ATGGCTCTCCTCâ AGCGTà TTCà ACAà GGGGCTGà AGG 438 GGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGG 478 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
M R E S - H llL> p C C L -E G F P -IR E S -H l1 L ATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTACACATGCTTTA 498 ATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTACACATGCTTTA 538 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
M R E S - H llL> pCCL-E G FP-IR E S-H 11L CATGTGTTTAGTCGAGGTTAAAÀÀAACGTCTÂGGCCCCCCGAACCÂCGGGGACGTGGTTT 558 CATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTT 598
I then inserted the M11L fragment, whose presence was verified using M11L 
specific primers. The insert was verified by DNA sequencing and compared to 
the consensus EGFP sequence (Fig. 6; accession number U55762).
To show that both genes were being expressed, I transduced HEK293T 
cells with each transfer vector. EGFP expression was assessed by flow 
cytometry, while M11L expression was detected by western blotting (Fig. 7). As 
expected, I observed EGFP expression in all of the vectors examined (Fig. 7A). 
The pCCL-EGFP vector was observed to have the highest MFI of all vectors, 
126.1 ±53.7. Furthermore, the level of EGFP expression was lower but not 
significantly when transducing with pCCL-EGFP-IRES-M11L, which had an MFI 
of 40.3. Interestingly, the pCCL-EGFP-minCMV-hPGK-Luc vector displayed an 
MFI of 106.5, similar to that of pCCL-EGFP. However, it did trend towards a 
lower difference with its companion pCCL-EGFP-minCMV-hPGK-M11L than with 
the IRES containing vectors (Fig. 7 A top graph). The high variability in the level 
of EGFP expression may be explained by the use of different virus stocks in each 
attempt. When assessing M11L expression, I included the pHERO-M11 L-CpG- 
gp140-EGFP vector as a control, which was shown previously to express M11L 
(143). Both the pCCL-EGFP-IRES-M11L and pCCL-EGFP-minCMV-hPGK-MI 1L 
vectors expressed M11L (Fig. 7B).
Effect of M11L On Staurosporine-induced Apoptosis
I next wanted to examine if M11L transduction resulted in protection from 
apoptosis. As rat L cells were previously used in the characterization of the anti-
54
Figure 6 -  Sequence analysis of pCCL-EGFP-minCMV-hPGK-M11L lentiviral 
transfer vector. The M11L gene was inserted downstream of the hPGK promoter. 
Sequencing was performed using an outward N-terminus EGFP sequencing 
primer. Shown is the alignment of the hPGK promoter controlling M11L 
expression, and the M11L gene.
pCCL-EGFP-m inhCM V-hPGK-M llL
>M11L -------------------------------------- ATGATGTCTCGTTTAAAGACGGCCGTATA 29>pCCL-EGFP-rninCHV-hPGK-M llL GGGGGATCCCCCGGGCTGCAGATGATGTCTCGTTTAAAGACGGCCGTATA S50
**** ***** ***** ***** ***** *****>M11L CGATTATCTGAACGACGTGGATATAACGGAGTGTACGGAAATGGATCTAC 79>pCCL-ECFP-m inCH V -hPG K-H llL  CGÀTTATCTGAACGACGTGGATATAACGGAGTGTÀCGGAÂATGGATCTAC 600
* * * * * * * * ** * * * * * * * * * * * * * * * ** * * * * * * * * * * * * * * ** * * * * * * *
>M11L>pCCL-EGFP-m inCHV“ hPG K -H UL TGTGTCAGTTGAGTAATTGTTGCGATTTTATCAACGAAACGTACGCAAAA TGTGTCÀGTTGAGTAATTGTTGCGATTTTATC AACGAAACGTACGCAAAA
**** **** ***** ***** ***** ***** ***** ***** ***** ****** *
129650
>M11L>pCCL-EGFP-rninCHV-hPGK“ H llL AACTACGACACGTTGTATGATATCATGGAACGGGACATTTTGTCGTATAAAACTACGACACGTTGTATGÀTATCÀTGGAACGGGACATTTTGTCGTATAA
**************************************************
179700
>M11L TATCGTGAACATTAAAAATACGTTGACGTTCGCGTTACGAGACGCGTCAC 229>pCCL»EGFP-niinCM V-hPGK-HllL TATCGTGAACATTAAAAATACGTTGACGTTCGCGTTACGAGACGCGTCAC 7S0
******* ** **** ***** ***** ***** ***** ***** ***** ****** *
>hPGK CCGGTAGGCGCCAACCGGCTCCGTTCTTTGGTGGCCCCTTCGCGCCACCT 50>pCCL-EGFP-m xnCHV-hPGK-M HL CCGGTAGGCGCCAACCGGCTCCGTTCTTTGGTGGCCCCTTCGCGCCACCT SO
**************************************************>hPGK TCTACTCCTCCCCTAGTCAGGAAGTTCCCCCCCGCCCCGCAGCTCGCGTC 100>pCCL-EGFP-roinCMV-hPGK-MHL TCTACTCCTCCCCTAGTCAGGAAGTTCCCCCCCGCCCCGCAGCTCGCGTC 100
**** **** ***** ***** ***** ***** ***** ***** ***** ****** *>hPGK GTGCÀGGACGTGÀCAAÀTGGAAGTAGCACGTCTCACTAGTCTCGTGCAGÀ 150>pCCL-EGFP-mxnCMV-hPGK-MHL GTGCAGGACGTGACAAATGGAAGTAGCACGTCTCACTAGTCTCGTGCAGA 150
**************************************************>hPGK TGGACAGCACCGCTGAGCAATGGAAGCGGGTAGGCCTTTGGGGCAGCGGC 200>pCCL-EGFP-tninCKV-hPGK-H H L TGGACAGCACCGCTGAGCAATGGAAGCGGGTAGGCCTTTGGGGCAGCGGC 200
**************************************************>hPGK>pCCL-EGFP-»inCH V-hPGK -H l1L CAATAGCAGCTTTGCTCCTTCGCTTTCTGGGCTCAGAGGCTGGGAAGGGGCAATAGCAGCTTTGCTCCTTCGCTTTCTGGGCTCAGAGGCTGGGAAGGGG
* * ****** ***** ***** ***** ***** ***** ***** ***** ****** *
2 50 2 50
>hPGK TGGGTCCGGGGGCGGGCTCAGGGGCGGGCTCAGGGGCGGGGCGGGCGCCC 300>pCCL-EGFP-m lnCM V-hPGK-HHL TGGGTCCGGGGGCGGGCTCAGGGGCGGGCTCAGGGGCGGGGCGGGCGCCC 300
* * ****** ***** ***** ***** ***** ***** ***** ***** ****** *>hPGK> p C C L-E G F P -»in C H V -h P G K -H llL GAAGGTCCTCCGGAGGCCCGGCATTCTGCACGCTTCAAAAGCGCACGTCTGAAGGTCCTCCGGAGGCCCGGCATTCTGCACGCTTCAAAAGCGCACGTCT
**** **** ***** ***** ***** ***** ***** ***** ***** ****** *
350350
>hPGK GCCGCGCTGTTCTCCTCTTCCTCATCTCCGGGCCTTTCGACCTGCAGCC 399>pCCL-EGFP-m lnCH V-hPGK -H llL  GCCGCGCTGTTCTCCTCTTCCTCATCTCCGGGCCTTTCGACCTGCAGCC 399
Figure 7 -  Protein expression in transduced HEK 293T cells. HEK 293T cells 
were transduced with the designated lentiviral vector at an MOI of 5 and 
analyzed 48 hours later. (A) Representative data showing the level of EGFP 
transduction and intensity in cells transduced with the designated viral vector. 
Upper graph compares EGFP expression in paired experiments in transduced 
cells. Horizontal bar represents mean of data. Bottom graph shows pooled data 
representative of n=3 (pCCL-EGFP and pCCL-EGFP-IRES-M11L) or n=2 (pCCL- 
EGFP-minCMV-hPGK-Luc and pCCL-EGFP-minCMV-hPGK-M11L) independent 
experiments. Student’s t test was used to compare pCCL-EGFP with pCCL- 
EGFP-IRES-M11L and pCCL-EGFP-minCMV-hPGK-Luc with pCCL-EGFP- 
minCMV-hPGK-M11L. (B) Western blot showing M11L expression in transduced
cells.
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apoptotic properties of M11L (143), , I transduced rat L cells with pCCL-EGFP or 
pCCL-EGFP-IRES-M11L at an MOI of 5. Transduced and non-transduced cells 
were treated with 4pM STS or a DMSO control for 8 hours, 48 hours following 
transduction. STS functions as a general kinase inhibitor, leading to apoptosis 
through the intrinsic pathway. In order to specifically examine the population of 
transduced cells, I gated on EGFP+ cells (as shown on Figure 8A Column 2). 
Levels of viability and apoptosis were determined by staining using annexin V 
and 7-AAD. Exclusion of both dyes represents viable cells, annexin V+ cells are 
early apoptotic, and annexin V+ 7-AAD+ cells are late apoptotic or already dead.
I first observed viability and apoptosis profiles in transduced and 
untransduced cell populations 48 hours after infection, in the absence of an 
apoptotic inducer (Fig 8). Untransduced cells were 95.3±0.8% viable (annexin V  
7-AAD'), whereas pCCL-EGFP and pCCL-EGFP-IRES-M11L transductants were 
90.8±1.7% and 86.2±7.4% viable respectively. The high initial viability was also 
reflected in a small population of early and late apoptotic cells. Untransduced 
cultures were 2.4±0.4% annexin V+ 7-AAD", in comparison to the pCCL-EGFP 
transductants, 5.3±1.2%, and pCCL-EGFP-IRES-M11L transductants which were 
7.7±4.4%. Examination of the late apoptotic population showed sizes of 
1.1 ±0.4% in untransduced cells, 2.4±0.6% in pCCL-EGFP transductants, and 
5.0±2.2% in pCCL-EGFP-IRES-M11L transductants. None of the differences 
were observed to be significant following two way ANOVA testing. These results 
show that the transduction process did not result in any significant insult to 
viability of the cells.
Figure 8 -  Viability profiles of transduced L cells following staurosporine induced 
apoptosis. Mouse L cells were transduced with pCCL-EGFP or pCCL-EGFP- 
IRES-M11L at an MOI of 5. Two days following transduction, L cells were 
cultured in complete DMEM containing 4pM STS for 8 hours. Following this, cells 
were washed and stained using 7-AAD and annexin V to detect apoptosis. 
pCCL-EGFP and pCCL-EGFP-IRES-M11L cells were previously gated on the 
EGFP+ population. (A) Representative data showing viability profiles of treated 
cells. Column 1 shows viability profile of untransduced cells. Column 2 shows 
gating of EGFP+ populations in transduced cell populations. Column 3 shows 
viability profile of total cell population in transduced cultures. Column 4 shows 
viability profile of EGFP+ cells only in transduced populations based on gating in 
column 2. (B) Graph of pooled data. Representative of n=3 independent 
experiments. Two way ANOVA testing was performed to determine any 







Next I examined the effects of STS treatment on the untransduced and 
transduced cultures (Fig. 8A rows 2 and 4). Treatment with STS resulted in a 
large decrease in viability in all cells. Untransduced cultures were 43.0±5.1% 
viable, 40.7±15.5% early apoptotic, and 2.6±0.9% late apoptotic. The pCCL- 
EGFP transductants decreased to 33.0±3.6% viable, an increased to 
50.3±14.3% early apoptotic and 4.6±1.4% late apoptotic. Similarly, the pCCL- 
EGFP-IRES-M11L transductants were 25.4±6.6% viable, 53.4±11.0% early 
apoptotic and 4.5±1.1% late apoptotic. However, I did not observe significant 
differences in viability or apoptosis levels between untransduced and transduced 
populations.
Short Term Effects of M11L Transduction
As mature DCs are required for immunogenicity, I wanted to determine if 
the transduction process affected the relative proportions of mature and 
immature DC populations, and if it decreased viability of these populations in the 
short term. This determination would allow us to observe if the transduction 
process resulted in an alteration of the cytokine environment that in turn would 
influence viability or the maturation profile independently of the genes being 
transduced. To do so, bone marrow cells were isolated from femurs and tibias of 
mice, cultured in IL-4 and GM-CSF and from these cultures, BMDCs were 
enriched 4 days later. Immediately following enrichment, DCs were transduced 
with the lentiviral vector. To begin, my studies focused on the pCCL-EGFP or 
pCCL-EGFP-M11L vectors. Infection proceeded for 24 hours, following which
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effects of virus treatment on the BMDC populations were assessed by examining 
viability and maturation via CD11c and CD86 expression.
As viability was a major problem using non-viral vector-mediated 
transfection, I first assessed whether transduction also had the same negative 
effects (Fig. 9, top row). To measure this, the BMDC cultures were stained with a 
fluorescent vital dye taken up by dead cells and whole culture viability was 
examined by flow cytometry. Untransduced cultures were 92.7 % viable. 
Transduction did not appear to have an effect on viability, as viability levels of 
92.4% and 90.6% were observed when using the pCCL-EGFP and pCCL-EGFP- 
IRES-M11L vectors respectively.
Since the maturation state of the BMDCs is relevant to their capacity to 
activate T cells, I examined the relative proportions of immature CD11c+CD86' 
and mature CD11c+CD86+ in total DC cultures described above (Fig. 9B). 
Untransduced DCs were seen to be 76.6% mature and 19.3% immature. 
Transduction with either vector did not appear to have a large impact on 
maturation, as pCCL-EGFP transduced cultures had a mature to immature ratio 
of 77.7% to 18.0%. Additionally, M11L expression did not appear to increase 
maturation as pCCL-EGFP-IRES-M11L transduced cultures were seen to be 
79.3% mature and 15.5% mature. These results suggest that transduction with 
these vectors had little to no effect on viability or the proportion of mature and 
immature cells in the total DC population.
Figure 9 -  Lentiviral transduction process does not affect DC maturation or 
viability. Primary murine BMDCs were isolated and transduced with pCCL-EGFP 
or pCCL-EGFP-IRES-M11L. Cells were harvested 24 hours following 
transduction and analyzed by flow cytometry for EGFP expression, viability and 
cell markers CD86 and CD11c. (A) Representative data showing analysis of 
viability of the DC cultures. At right, pooled data representative of n=2 
independent experiments. One way ANOVA testing was performed to determine 
any significant differences. (B) Representative data showing the gating of mature 
and immature DC populations based on CD11c and CD86 expression. Graph at 
right shows pooled data. One way ANOVA testing was performed independently 
on CD86' and CD86+ populations to determine any significant differences from 
the use of any vectors. (C) Representative data showing histograms of GFP 
expression in mature and immature DC fractions of pCCL-EGFP and pCCL- 
EGFP-IRES-M11L treated cultures. Scatter plot at right shows data from 2 













I also examined the level of EGFP expression in the mature and immature 
fractions (Fig. 9C). I observed that the pCCL-EGFP lentiviral vector transduced 
51 % of CD11 c+CD86' cells and 18.7% of CD11 c+CD86+ cells. The pCCL-EGFP- 
IRES-M11L vector also displayed an increased level of transduction in immature 
cells, 43.5%, compared to mature cells, 14.5%. Although the differences were 
not seen to be statistically different, there is a consistent trend towards 
transduction of predominantly immature cells.
Long Term Culture of Bone Marrow-derived DCs
Owing to the potential ability of M11L to protect BMDCs from apoptosis, I 
performed long term cultures of primary BMDCs to observe any effects of M11L 
transduction on longevity in vitro. To do so, bone marrow was harvested from 
femurs and tibias of mice, and differentiation into DCs was induced with IL-4 and 
GM-CSF and enriched for DCs 4 days later. Immediately following enrichment, 
cells were transduced with pCCL-EGFP and pCCL-EGFP-IRES-M11L. The 
transduced cells were then maintained in culture up to day 13, with media and 
cytokines (GM-CSF and IL-4) replenished every 3 days after enrichment. At days 
7, 10, and 13, cells were harvested and analyzed based on viability, and 
maturation state via flow cytometry. I analyzed the effects of transduction from 
two perspectives. Firstly, I determined if there were long-term effects of the 
transduction process on the total culture. Secondly, I specifically examined 
EGFP+ cells to determine the effects of M11L transduction on longevity of the
BMDCs.
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To determine if the virus transduction process affected maturation of the 
cultures in long-term, I examined the proportions of CD86' and CD86+ 
populations in untransduced and transduced cultures (Fig. 10). To do this, I 
gated on viable cells CD11c+ and examined the distribution of CD11c+ CD86+ 
and CD86' cells. In the untransduced cultures, the immature CD86" population 
initially comprised approximately 25.9% of total viable cells while the mature 
population comprised 63.2% of viable cells. The mature population steadily 
decreased over the course of the culture, eventually falling to approximately 
21.1%. Conversely, the immature population comprised more of the total viable 
cells by day 13, making approximately 61.7% of viable cells. Transduction with 
either virus did not appear to influence the maturation profile. Cultures 
transduced with pCCL-EGFP were initially 69.0% mature and 21.8% immature.
At day 13, the profile switched to 15.6% mature and 57.9% immature. In the case 
of pCCL-EGFP-IRES-M11L transduced cultures, the initial profile was 64.9% 
mature and 26.1% immature. As with the other cultures, there was a shift 
towards the immature fraction, becoming 12.6% mature and 67.3% immature. 
These results may suggest increased cell death among the mature population.
As I observed in the short-term study, there does not appear to be any lingering 
effects of the transduction process in the long-term study.
Due to the importance of maturation state in a DC vaccine, I examined the 
levels of EGFP expressing CD11 c+ CD86+ and CD11 c+ CD86' cells based on the 
gates shown in figure 10 over the time course to see the levels of transduction in 
mature and immature fractions in the total culture (Fig. 11). The percentage of
Figure 10 -  The process of virus transduction does not have a detectable affect 
on DC maturation in the long term. Primary murine BMDCs were isolated and 
transduced 4 days later with pCCL-EGFP or pCCL-EGFP-IRES-M11L. Cells 
were examined at days 7, 10, and 13 post transduction by flow cytometry for 
CD11c and CD86 expression. (A) Representative data showing CD86 and 
CD11c staining in DC cultures collected at the time point shown (days post 
BMDC isolation). (B) Graph representing pooled data. Day 7 and 10 are 
representative of 2 experiments. Day 13 representative of 1 experiment. One 
way ANOVA testing was performed between the three groups on each day to 
determine any significant differences.
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immature EGFP+ pCCL-EGFP transductants increased from 55.0% to 68% by 
the end of the culture. However, there was a greater increase in the percentage 
of EGFP+ mature cells, which increased to 70.1% from 30.9%. In the case of 
pCCL-EGFP-IRES-M11L transduced cultures, the level of EGFP+ immature cells 
showed an overall decrease to 21.2% from an initial level of 30.2%. Conversely, 
the level of EGFP+ mature cells increased from 14.7% to 21.7%. Repeats were 
performed using different virus stocks, possibly resulting in the variable levels of 
transduction. However, consistent to all trials was the difference in EGFP MFI 
observed when comparing pCCL-EGFP transduced cells to pCCL-EGFP-IRES- 
M11L transductants.
To determine if transduction of DCs with M11L resulted in less cell death, I 
examined the change in viability of both transduced and untransduced 
populations over the 13 day time course in the same population of cells analyzed 
in Figures 10 and 11 (Fig. 12A, top graph). I first examined the rate of death in 
the total culture to see if globally, all cultures were dying at approximately the 
same rate. To do so, I gated on total CD11c+ cells. The untransduced culture 
decreased in viability from 80.3% to 46.5% at day 13. The transduced cultures 
also had a similar day 7 viability, 79.6% for pCCL-EGFP and 76.3% for pCCL- 
EGFP-IRES-M11L). As with the untransduced cultures, there was a drop in 
viability by day 13, as pCCL-EGFP transduced cultures were 43.4% viable, and 
pCCL-EGFP-IRES-M11L transduced cultures were 47.3% viable. This suggests 
that from a general outlook, each culture was dying at the same rate. Following
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Figure 11 -  The level of GFP+ mature DCs Increases over time. Primary murine 
BMDCs were isolated and transduced 4 days later with pCCL-EGFP or pCCL- 
EGFP-IRES-M11L. Cells were examined at days 7, 10, and 13 post transduction 
by flow cytometry for EGFP expression in the mature CD86+ and immature 
CD86' populations. (A) Representative data showing the level of EGFP 
expression in pCCL-EGFP and pCCL-EGFP-IRES-M11L mature and immature 
cells. (B) Graph representing pooled data. Day 7 and 10 are representative of 2 
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this observation, I wanted to see specifically how levels of transduced EGFP+ 
cells related to the decrease in total culture viability.
I next examined the persistence of transduced EGFP+ DCs in the culture 
(Fig. 12B). To do so, I gated on viable CD11c+ cells and measured the level of 
transductants up to day 13. The pCCL-EGFP transductants comprised 36.7% of 
viable CD11 c+ cells at day 7, and increased to 69.7% at day 13. Conversely, 
pCCL-EGFP-IRES-M11L transductants were initially 28.0% of viable CD11c+ 
cells, increasing to 42.0%. However, the sizes of both EGFP+ populations appear 
to trend towards an increase as the average population size nearly doubles. It 
would appear as though in the long term study, the transduced cells persist 
longer; however M11L expression does not appear to have a significant effect.
DC Maturation Cocktail Does Not Appear to Increase Mature Transductants
The importance of mature DCs in modulating the immune response is well 
understood. However, I have observed in my transduction studies that the level 
of EGFP+ CD11 c+ CD86+ population was lower than that of the EGFP+ CD11 c+ 
CD867 Therefore, I attempted to see if the application of a maturation cocktail to 
the DC cultures following transduction would increase the number of mature 
transductants. To do this, I treated the cells with a previously characterized 
maturation cocktail consisting of IL-1(3, TNF-a, IL-6, CpG, and PGE2, 24 hours 
after transduction; thus, transduced immature cells would undergo maturation. 
The DCs were subjected to the maturation cocktail for another 16 hours prior to 
analysis by flow cytometry.
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Figure 12 -  Effect of M11L expression on DC viability in vitro. Primary murine 
BMDCs were isolated and transduced 4 days later with pCCL-EGFP or pCCL- 
EGFP-IRES-M11L. Cells were examined at days 7, 10, and 13 post transduction 
by flow cytometry for EGFP expression in the mature CD86+ and immature 
CD86' populations. (A) Representative data showing gating of viable CD11c+ 
cells at each day, and graph shows pooled data from n=2 independent 
experiments. (B) Representative data showing EGFP expression in viable 
CD11c+ populations. Graph shows pooled data from n=2 independent 
experiments
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I observed that administration of the maturation cocktail did not affect 
viability of the cells (Fig. 13A, top row). Untransduced DCs treated with the 
cocktail were observed to be 92.7% viable. Transduction with pCCL-EGFP 
resulted in 91.4% viable cells, and pCCL-EGFP-IRES-M11L treated cultures 
were 91.1% viable. As these numbers are similar to viability levels of DC cultures 
24 hours post-transduction, it appears as though the cocktail did not affect 
viability. As expected, the maturation cocktail resulted in a shift towards a CD86+ 
state (Fig. 13A, bottom row). Untransduced cultures shifted to 88.2% mature and 
7.5% immature. The pCCL-EGFP transduced cultures were 87.0% mature and 
8.3% immature. Lastly the pCCL-EGFP-IRES-M11L transductants were 87.8% 
mature and 7.5% immature.
Next, I examined the level of EGFP expression in the mature and 
immature fractions from a standpoint of transduction efficiency and level of EGFP 
expression by MFI (Fig. 13B). I observed that regardless of the lentiviral vector, 
higher numbers of transductants were seen in the immature fraction. In cultures 
without the maturation cocktail, the pCCL-EGFP vector transduced 60.1% 
immature cells and 28.9% mature cells. The pCCL-EGFP-M11L vector displayed 
a much lower transduction efficiency, at 14.4% mature cells, and 9.1%mature 
cells. In cocktail treated cultures, the pCCL-EGFP vector transduced 54.4% of 
immature cells and 32.7% of mature cells. The pCCL-EGFP-M11L vector overall 
again transduced fewer cells, 12.4% immature compared to 9.1% of mature cells.
The MFI resulting from pCCL-EGFP transduction was also higher in all 
cases. Taken together, these results demonstrate that the inclusion of the 1RES-
Figure 13 -  Administration of a maturation cocktail does not greatly increase the 
level of mature GFP+ BMDCs. Primary murine BMDCs were isolated and 
transduced 4 days later with pCCL-EGFP or pCCL-EGFP-IRES-M11L. Twenty- 
four hours following transduction, BMDCs were cultured in the presence of a 
maturation cocktail consisting of IL-ip, TNF-a, IL-6, CpG, and PGE2 for 16 
hours. Cells were then collected and analyzed by flow cytometry for viability, 
GFP, CD11c, and CD86. (A) Representative data showing gating of viable cells, 
and of mature and immature DC populations. (B) Flistograms depicting GFP 
expression in pCCL-EGFP and pCCL-EGFP-IRES-M11L transduced cells in the 












M11L sequence negatively affects the level of transduction by the lentiviral 
vectors. Furthermore, regardless of the expression vector used, there appears to 
be a bias towards the infection of immature DCs. Use of the maturation cocktail 
does not appear to greatly influence the proportion on mature transductants.
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Discussion
The high capacity of DCs to initiate an immune response makes them an 
attractive option for immunotherapy. However, an efficient gene transfer method 
is required in order to efficiently introduce the antigen into DCs for vaccination 
purposes. I have assessed both non-viral and viral vector-mediated methods of 
gene transfer and observed that viral-vector mediated gene transfer provided the 
best balance between viability and efficiency of what????.. Using the pCCL- 
EGFP vector, I observed upwards of 40% transduction efficiency 48 hours after 
infection in BMDCs. However, the IRES-containing bicistronic vector appeared to 
transduce DCs far less efficiently, transducing slightly more than 10% of DCs at 
48 hours post-infection. Curiously, I observed that pCCL-EGFP-IRES-M11L 
expressed EGFP at considerably reduced levels as compared with pCCL-EGFP. 
From my results, it is unclear if this is a direct result of M11L expression, the 
presence of an IRES, or the size of the integration cassette. Transduction with 
any of the viral vectors did not result in a large decrease in viability. Conversely, I 
have shown that conventional transfection reagents such as Lipofectamine or 
Turbofect do not mediate a high transfection efficiency of DCs. In my trials, I 
never observed transfection efficiencies greater than 5% with either method, 
while viability was a major problem also. Nucleofection resulted in the highest 
transfection efficiency of the three methods tested. However, it also had the 
lowest viability. This result coupled with the limited number of cells one can use 
in a single transfection, greatly limits the overall number of transfected cells that
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expression by Langerhans cells results In the maturation of these cells, their 
migration to the lymph nodes, and induction of an HIV-specific Th1 immune ' 
response. The system was initially characterized using a simian HIV-based DNA 
construct, which showed a decrease in viral rebound when administered with 
HAART therapy (181). Later studies showed that DermaVir was capable of 
inducing HIV-specific CD8+ effector and central memory responses (182). This 
form of therapy has shown clinical potential, as it has been cleared for Phase II 
clinical trials.
In order to assess if the level of M11L expression in the generated vector 
is sufficient for protection from apoptosis, I used pharmacological induction of 
apoptosis. The previous characterization of M11L function made use of 
immortalized cells treated with STS to induce apoptosis (141). I observed that 
transduction with my viral vectors did not result in a decrease in viability of the 
target L cells. Following STS treatment, M11L expression did not appear to result 
in any protective effect as viability levels appeared to decrease but not 
significantly. Population sizes of the primary apoptotic (annexin V+ 7-AAD') and 
secondary apoptotic (annexin V+ 7-AAD+) were also examined. I did not notice 
any significant differences arising from STS treatment following transduction in 
either population. However, the late apoptotic population in pCCL-EGFP-IRES- 
M11L transductants did not appear to change following STS treatment, whereas 
the same population in untransduced and pCCL-EGFP transduced cells 
increased nearly 2-fold. This result may suggest a slight protective role by M11L.
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In future experiments, the STS treatment experiment can be replicated in 
primary BMDCs. Although DCs in vivo are triggered to undergo apoptosis via the 
extrinsic pathway due to Fas-FasL interactions with CD8+ T cells, induction of 
apoptosis may result in clearer observations than the long term culture. A step 
further than this would be to use the Fas-FasL interactions in DCs to consolidate 
the effects of M11L on the intrinsic and extrinsic apoptotic pathways. However, 
as the intrinsic and extrinsic pathways converge at the level of the mitochondria, 
it would be expected that both STS treatment and Fas-FasL interactions in DCs 
would have similar results. Alternatively, apoptosis levels may also be measured 
by examining the levels of mitochondrial proteins associated with apoptosis, 
including cytochrome c which is released into the cytoplasm due to the effects of 
Bak and Bax.
The discovery of an efficient and safe method of gene delivery to DCs is 
only one obstacle in the generation of DC-based vaccines. The immune 
response generated from such a vaccine ultimately depends on maturation and 
activation of the genetically engineered DCs. Firstly, I observed that transduction 
of a primary BMDC population did not have an effect on the proportion of mature 
versus immature cells. This is in agreement with findings from other groups that 
also performed phenotypic studies of lentivirus transduced DCs (183). In one 
study, they made use of the same three plasmid system, including a GFP 
expression transfer vector. They observed no increase in the mean fluorescence 
of total culture CD86. Secondly, transduction with M11L did not influence the 
maturation state either. Interestingly, I consistently observed a greater portion of
the EGFP+ cells residing within the Immature CD86' population. This may be 
explained by as of yet unknown restriction factors present within the mature 
CD86+ population or a bias towards the infection of immature cells. Similar 
mechanisms are observed in CD4+ T cells, where their activation state can 
influence susceptibility to infection by HIV-1 (184). Research conducted in 2007 
by Dong et al. demonstrated that HIV-1 Infection may be restricted in some 
subsets of mature DCs (184). Specifically, they found that LPS orTNF-a-matured 
DCs restrict HIV infection post-entry, at the level of reverse transcription and 
integration. Other groups have reported the selective infection of a subset of 
nonmaturing DCs in human blood, and the prevention of maturation by reducing 
antigen expression in infected cells. If a similar process exists in murine DCs, It 
may be responsible for preventing efficient transduction of mature DCs.
I performed a long-term DC culture in order to determine if transduction or 
the expression of M11L would have any effects on the DCs up to 13 days 
following isolation. In my observations, all transductants appeared to persist 
longer than non-transduced cells. In the total DC populations, I observed a 
general decline in total culture viability. However, at later time points, the sizes of 
the transduced cell populations increased relative to the size of the viable 
CD11c+ population. However, these effects appear to be minimal in these 
experiments as statistical significance was not observed. It is possible, however, 
that further differences may arise at later time points.
To circumvent problems with direct infection of mature DCs, I 
administered a previously characterized maturation cocktail. The rationale behind
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this was that immature DCs would first be transduced.with the viral vectors. The 
experiment I performed consisted of an initial transduction, followed 24 hours 
later by administration of the maturation cocktail. Because of the HIV-restrictive 
nature of TNF-a matured DCs (184), it appears unlikely that a reversal of the 
order of transduction and cocktail administration would increase EGFP+ CD86+ 
cells. Following this, administration of the maturation cocktail would push the 
transduced immature cells into the mature fraction. As expected, there was a 
shift in the overall DC population towards a CD86+ mature state seen in both 
transduced and untransduced populations. Interestingly, I observed an increase 
in EGFP+ CD86+ cells in the populations transduced with pCCL-EGFP. This was 
concordant with a slight decrease in the EGFP+ CD86' population. Another study 
by Toscano et al. showed that LPS treatment following lentivirus transduction of 
DCs resulted in a greater than 4 fold increase in CD86 expression (183). This 
may in part be explained by the fact that they assessed CD86 within the whole 
culture rather than specifically those DCs that were transduced. This 
phenomenon was not observed in cells transduced with pCCL-EGFP-M11L; 
rather, the proportion of CD86' and CD86+ cell populations did not change. 
Potentially, M11L may be exerting previously unknown effects on DC maturation. 
Such phenomena have yet to be examined as this is the first study that has 
attempted to express M11L in dendritic cells. However, it has been observed that 
poxviruses can inhibit DC maturation (185, 186). In order to determine the 
effectiveness of M11L inclusion, it will be necessary to determine if it has an
additional role in preventing DC maturation, as this has not been previously 
studied.
As the maturation state of the DCs will dictate its effectiveness in 
immunotherapy, it is important to determine a method that is suitable to mature 
or activate a large number of DCs. A recent method makes use of an inducible 
CD40 system (187). CD40, a TNF family receptor, normally interacts with its 
cognate ligand, CD40L expressed on CD4+ T helper cells. The CD40-CD40L 
interaction results in increased antigen presentation and costimulatory capacity, 
as well as the synthesis of cytokines and anti-apoptotic molecules that all serve 
to enhance DC-mediated activation of CD8+ T cells. In 2005, the group of Hanks 
et a/, engineered an inducible CD40 system consisting of the cytoplasmic tail 
fused to a membrane bound drug binding domain (188). They demonstrated that 
primary BMDCs transduced with an adenovirus vector encoding the inducible 
receptor significantly increased levels of polarizing IL-12. Furthermore, use of 
inducible CD40 in a DC-based vaccine against OVA-peptide resulted in 
decreased EG.7-OVA tumor size. Co-expression of inducible CD40, M11L, and 
an immunogenic protein should provide an extremely robust immune response. 
However, one of the difficulties here would be the number of genes that have to 
be transferred. As observed in my studies, as well as others; gene transfer of one 
gene is already difficult. As such, it is still necessary to revise existing gene 
transfer methods to allow for triple gene synthesis.
Expression of M11L from the IRES may be resulting in levels that are too 
low to be effective (161). A possible cause for this may be the errors present in
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the IRES sequence as this may affect IRES functionality. If the sequence 
variations occur in critical regions of the secondary structure formed by the IRES, 
loading of the translation initiation factors may be altered, potentially decreasing 
the level of translation. Based on my observations in HEK293T cells, however, 
complete IRES function did not appear to be abrogated as expression of M11L 
was verified in transduced cells. To verify that effective levels of M11L are being 
produced, M11L transduction can occur in parallel with myxoma virus infection to 
determine if M11L expression is comparable.
In order to examine this possibility, I have begun to study a second 
transfer vector system that makes use of two separate promoters oriented in 
opposite direction (164). Characterization of this system showed increased 
expression of the second gene. This may translate to an increased expression of 
M11L. Also, depending on the relative amounts of expression, it may also be 
possible to reverse the order of the genes encoded within the IRES containing 
transfer vector. In practice, this would depend on the level of expression required 
of an immunogenic peptide. In the case of GFP, studies have reported detectable 
levels of GFP expression when under the control of the EMCV IRES. A third 
possibility would be to use the foot and mouth disease virus (FMDV) protein 2A 
(189, 190). The 2A region acts as an intergenic cleavage site. Furthermore, the 
cleavage event does not require additional proteases, rather it is believed to 
occur due to conformational strain placed at the site of the 2A sequence during 
translation. However, when deciding on the method of dual gene expression, it is 
important to note that overexpression of M11L may also be cytotoxic. As such, it
may be necessary to explore other possible anti-apoptotic genes. Selecting the 
appropriate method for gene expression is not simply the one that results in the 
highest level of expression, but rather a fine balance must be obtained.
Two points raised by the transduction of these cells are the migratory 
capacity of the transduced DCs, as well as their actual persistence within 
regional lymph nodes. A phenotypic study of lentivirus transduced DCs showed 
that following transduction and LPS treatment, CCR7 expression increased, 
making the cells more responsive to lymph node-associated chemokine CCL19, 
suggesting normal migratory function (183). A separate group transduced DCs 
with an adenoviral vector expressing both EGFP and a hyperactive Bcl-xL mutant 
and assessed both migration and persistence of the transduced DCs within the 
lymph node (127). They observed higher accumulation of DCs transduced with 
the B c I-Xl mutant resulting in prolongation of the duration of DC presence within 
the lymphnode. In agreement with previous studies, they also noted a decline in 
DC accumulation at the lymph node beginning 2 days after injection.
Once M11L expression is verified and levels of both genes within the 
transfer vector are optimized, further experiments can be performed to examine 
migration, persistence, and immunogenicity of the transgenic DCs. Previous 
research from my laboratory has shown that following footpad injection, PKH- 
green labeled DCs migrate to popliteal lymph nodes and persist for upwards of 4 
days, peaking at day 2 post-injection. A similar schema can be performed using 
the transduced DCs. In order to separate transduced, non-transduced, and 
endogeneous DCs, the DC population to be injected can be labeled with PKH
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red, prior to injection. I would expect to see results similar to those observed by 
the group of Yoshikawa et al. in 2008; similar migration levels of transduced and 
untransduced DCs were observed, but with increased persistence within the 
lymph node in the case of the former population (127). However, different 
methods of analysis can be performed to overcome the shortcomings of their 
quantitation techniques. While EGFP is necessary for the initial characterization 
and analysis of migration and persistence, it will be replaced with gp140 in order 
to assess immunogenicity of the DC vaccine in BALB/c mice, which exhibit 
known immune responses to the HIV envelope. Work here has begun as the 
appropriate pCCL-gp140 lentiviral vector has been generated.
To assess immunogenicity of the virus, it will be possible to use a variety 
of different proteins. However, due to the anti-apoptotic effects of M11L, the 
system should be able to accommodate what are normally cytotoxic proteins 
when overexpressed, notably the HIV env gene. The findings from the pHERO 
system demonstrate that M11L is able to increase immunogenicity of gp140 in 
the context of a DNA vector vaccine (143). In order to do this, the same schema 
can be performed as with the migration studies. However, instead of imaging 
lymph nodes, effector activity of splenic or lymph node T cells against the model 
epitope can be assessed ex vivo.
Summary
In my studies, I have observed the inefficiency of DC transfection using 
non-viral methods. As such, viral transduction was required in order to generate
transgenic DCs on a large enough scale. Consistent with previous findings, 
transduction of DCs does not appear to greatly affect viability and maturation. 
However, I have observed an increased propensity for the lentiviral vectors to 
transduce and exist in the immature DC population. M11L transduction did not 
appear to influence the relative proportions of mature and immature populations. 
However, its presence in the vector with the IRES did appear to decrease EGFP 
expression with respect to MFI and the number of transductants. M11L 
expression did not appear to have any major impact in viability in the long term 
culture, and this observation may have resulted from a level of expression too 
low to be effective. As a result, I have begun studying another bicistronic vector 
that should permit greater expression as it makes use of another promoter rather 
than an IRES. Optimization of the bicistronic vector and expression level of M11L 
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Appendix 1. Proof of ethics approval. A copy of the document showing official 
approval from the University Council on Animal Care for using the C57BI/6 mice 
for DC studies.
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